


Synthesis of 3'-Deoxy-3'-difluoromethyl Azanucleosides from trans-4-Hydroxy-L-proline

Xiao-Long Qiu[§] and Feng-Ling Qing*,^{§,‡}

Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Science, 354 Fenglin Lu, Shanghai 200032, China, and College of Chemistry and Chemistry Engineering, Donghua University, 1882 West Yanan Lu, Shanghai 200051, China

flq@mail.sioc.ac.cn

Received January 11, 2005



Two strategies were tried to synthesize 3'-deoxy-3'-difluoromethyl azanucleosides. After the failure of the first route, the key intermediate 12 from *trans*-4-hydroxyproline 7 in 8 steps was stereoselectively prepared. The alcohol 12 was subjected to selective protection, oxidation, and difluoromethylenation to afford the fluorinated compound 18, whose hydrogenation was then systematically investigated. After a series of transformations of protecting groups, the resultant compounds 22 and 23 were oxidized to the desired lactams 24 and 25, which were successfully utilized to synthesize our target molecules, 3'-deoxy-3'-difluoromethyl azanucleosides 33, 34a, 34b, and 35.

Introduction

In general, nucleosides, consisting of both a base moiety and a sugar moiety, are classified into two major divisions, that is, *N*-nucleosides and *C*-nucleosides.¹ *N*-Nucleosides feature a bond between the anomeric carbon of the sugar moiety and the nitrogen of the base moiety. *C*-Nucleosides have a bond between the anomeric moiety and the carbon of the base moiety. Further, the nucleosides, wherein carbon, sulfur, phosphorus, and nitrogen substitute for the sugar ring oxygen, are commonly defined as carbocyclic nucleosides,² thionucleosides,³ phosphanucleosides,⁴ and azanucleosides,¹ respectively. Nucleosides and nucleoside analogues, known to be DNA and RNA subunits, have achieved considerable success in the fight against viral infection. For the last two decades, some high biological nucleoside and nucleoside analogues have been synthesized, studied, and used. For example, the 5-iodo-2'-deoxyuridine (IDU) was licensed as the first nucleoside antiviral, and the first antiviral chemotherapeutic agent for use in humans.⁵ The 2',3'-dideoxynucleosides (ddNs) have thus far proven to be the most effective therapeutic agents against human immunodeficiency virus (HIV)⁶ and hepatitis B virus (HBV).⁷ 3'-Azido-2',3'-dideoxythymidine (AZT),⁸ 2',3'dideoxyinosine (DDI),⁹ and 2',3'-dideoxycytidine (DDC)¹⁰

^{*}To whom correspondence should be addressed. Fax: 86-21-64166128.

 [§] Shanghai Institute of Organic Chemistry.
 [‡] Donghua University.

⁽¹⁾ Yokoyama, M.; Momotake A. Synthesis 1999, 1541.

⁽²⁾ For carbocyclic nucleoside reviews, see: (a) Crimmins, M. T. Tetrahedron 1998, 54, 9229. (b) Borthwick, A. D.; Biggadike, K. Tetrahedron 1992, 48, 571. (c) Agrofoglio, L.; Suhas, E.; Farese, A.; Condom, R.; Challand, S. R.; Earl, R. A.; Guedj, R. Tetrahedron 1994, 50, 10611. (d) Marquez, V. E.; Lim, M.-U. Med. Res. Rev. 1986, 6, 1. (e) Vine, R.; Akella, L. B. Med. Res. Rev. 1996, 52, 2789.

⁽³⁾ Yokoyama, M. Synthesis 2000, 1637.

⁽⁴⁾ Yamashita, M.; Kato, Y.; Suzuki, K.; Reddy, P. M.; Oshikawa, T. Abstr. 29th Congress Heterocycl. Chem. **1998**, 461.

⁽⁵⁾ Kaufman, H. E. Proc. Soc. Exptl. Biol. Med. 1962, 109, 251.

have also been approved for the treatment of AIDS. However, some nucleosides have shown limited stability, high toxicity, and lower bioactivity, so development of new antiviral and anticancer nucleoside analogues is intensively demanded despite great improvements against virus and cancer.

Recently, fluorinated nucleosides, containing fluorine atom(s) or fluorine-containing groups in the sugar moiety or the base moiety of nucleoside, have drawn increasing attention due to the introduction of the fluorine atom(s) into some nucleosides resulting in great improvement of bioactivity and stability of the corresponding compounds.¹¹ Perhaps the best known of the fluorinated nucleosides are 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine (FMAU),¹² 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-5-iodocytosine (FIAC),^{12b} 1-(2-deoxy-2-fluoro-β-Darabinofuranosyl)-5-ethyluracil (FEAU),13 3'-deoxy-3'fluorothymidine (FLT),¹⁴ 1-(2,3-dideoxy-2-fluoro- β -D-threopentofuranosyl)cytosine (F-ddC),¹⁵ 1-(2-deoxy-2-C-fluoromethyl-β-D-arabinofuranosyl)cytosine(SFDC),¹⁶ and 1-(2deoxy-2,2-difluoro- β -D-arabinofuranosyl)cytosine (Gemcitabine),¹⁷ all of which have high antiherpes activity, as well as antitumor activity in some cases. Although monofluorinated, gem-difluorinated, and trifluoromethylated sugar nucleosides, thionucleosides, and carbocyclic nucleosides have been widely studied, only a few fluorinated azanucleosides have been reported.¹⁸ Difluoromethylated (CHF_2-) and monofluoromethylated (CH_2F-) azanucleosides are attractive potential bioactive targets because of the unique properties of the two groups and azanucluosides. First, two groups have synthesized a series of azanucleosides and some of azanucleosides have proved active against human tumor cell lines.¹⁹ Second,

J. A. J. Med. Chem. 1991, 34, 2361. (b) Tiwari, K. N.; Secrist, J. A., III; Montgomery, J. A. Nucleosides Nucleotides 1994, 13, 1819

- (8) Yoshimura, Y.; Endo, M.; Miura, S.; Sakata, S. J. Org. Chem. 1999, 64, 7912.
- (9) Wang, P.; Hong, J. H.; Cooperwood, J. S.; Chu, C. K. Antiviral Res. 1998, 40, 19.
- (10) Young, R. J.; Shaw-Ponter, S.; Thomson, J. B.; Miller, J. A.; Cumming, J. G.; Pugh, A. W.; Rider, P. Bioorg. Med. Chem. Lett. 1995, 5, 2599.


(11) For fluoronucleoside reviews, see: (a) Bergstrom, D. E.; Swartling, D. J.; Libeman, J. F.; Greenberg, A.; Dolbier, W. R., Jr., Eds. Flurorine Containing Moleculars, Structure, Reactivity, and Applica*tions*; VCH: New York, 1988; pp 259–308. (b) Herdewijn, P.; Van Aerschot, A.; Kerremans, L. *Nucleosides Nucleotides* **1989**, *8*, 65. (c) Pankiewicz, K. W.; Watanabe, K. A. J. Fluorine Chem. 1993, 64, 15.
 (d) Pankiewicz, K. W. Carbohydr. Res. 2000, 327, 87.

(12) (a) Chu, C. K.; Ma, T.; Shanmuganathan, K.; Wang, C.; Xiang, Y.; Pai, S. B.; Yao, G. Q.; Sommadossi, J. P.; Cheng, Y. C. Antimicrob. Agents Chemother. 1995, 39, 979. (b) Watanabe, K. A.; Reichman, U.; Hirota, K.; Lopez, C.; Fox, J. J. J. Med. Chem. 1979, 22, 21.
(13) Su, T.-L.; Watanabe, K. A.; Schinazi, R. F.; Fox, J. J. J. Med.

Chem. 1986, 29, 151.

(14) (a) Etzold, G.; Hintsche, R.; Kowollik, G.; Langen, P. *Tetrahe-*dron **1971**, 27, 2463. (b) Balzarini, J.; Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E. Biochem. Pharmacol. 1988, 37, 2847.

(15) Okabe, M.; Sun, R.-C.; Zenchoff, G. B. J. Org. Chem. 1991, 56, 4392



the CF₂ and CHF groups have been proposed as reasonable isosteric and isopolar replacements for neutral oxygen, conferring phosphatase stability on nucleotide phosphate moiety.²⁰ Third, the CHF₂ and CH₂F groups have been employed ²¹ as preferable replacements for CH₃ in oligo(deoxyribonucleotide methyl phosphonate) due to its ability to act as a hydrogen donor,²² potentially allowing interaction with solvent and biological molecules. Fourth, replacements of the sugar ring oxygen of a nucleoside by nitrogen could cause the effects of biological significance. Besides the simple heteroatom effect of nitrogen,²³ nitrogen could bind with exceedingly high affinity and specificity to a variety of base-exicision DNA repair (BER) enzymes, which may suggest a transition-state model for the glycosyl transfer reaction leading to base excision.²⁴ On the basis of the above consideration and our ongoing efforts to develop new antiviral and anticancer agents, several difluoromethylated and monofluoromethylated azanucleosides were prepared in our group.^{18b,25} Here reported is our recent synthesis of 3'-deoxy-3'-difluoromethyl azanucleosides, starting from natural, cheap, and commercially available trans-4hydroxy-L-proline.

Results and Discussion

Attempt To Synthesize Target Molecules from L-Pyroglutamic Acid. On the basis of retrosynthetic analysis (Scheme 1), the target molecules A can be reached from the fluorinated intermediate **B**, which could be prepared from keto compound **C** via difluoromethylenation followed by hydrogenation. Selective protection of the two hydroxyl groups of **D** followed by oxidation of the residual hydroxyl group would furnish the lactam **C**. The alcohol **D** can be provided via dihydroxylation of the lactam **E**, which could be conveniently synthesized from L-pyroglutamic acid 1. It is noteworthy that the Bocprotecting groups of target molecules A could not be removed because the N-azanucleosides having a free NH group have proved to be unstable.²⁶

(22) Nelson, D. D., Jr.; Fraser, G. T.; Klemperer, W. Science 1987, 238, 1670.

(23) Akiba, K.-y. Yuki Gosei Kyokai Shi 1984, 42, 378.

(24) Schärer, Ö. D.; Verdine, G. L. J. Am. Chem. Soc. 1995, 117, 10781

(25) Qiu, X.-L.; Qing, F.-L. Bioorg. Med. Chem. 2005, 13, 277.

⁽⁶⁾ Parks, R. E., Jr.; Stoeckler, J. D.; Cambor, C.; Savarese, T. M.; Crabtree, G. W.; Chu, S.-H. In Molecular Actions and Targets for Cancer Chemothreapeutic Agents; Sartorelli, A. C., Lazo, J. S., Bertino, J. R., Eds.; Academic Press: New York, 1981; p 229. (7) (a) Secrist, J. A., III; Tiwari, K. N.; Riordan, J. M.; Montgomery,

⁽¹⁶⁾ Yoshimura, Y.; Saitoh, K.; Ashida, N.; Sakata, S.; Matsuda, A.

Bioorg. Med. Chem. Lett. 1994, 4, 721.
 (17) (a) Kotra, L. P.; Xiang, Y.; Newton, M. G.; Schinazi, R. F.;
 Cheng, Y.-C.; Chu, C. K. J. Med. Chem. 1997, 40, 3635. (b) Hertel, L. W.; Kroin, J. S.; Misner, J. W.; Tustin, J. M. J. Org. Chem. 1988, 53, 2406


^{(18) (}a) Qing, F.-L.; Yu, J.; Fu, X.-K. Collect. Czech. Chem. Commun. 2002, 67, 1267. (b) Qiu, X.-L.; Qing, F.-L. Synthesis 2004, 334.

^{(19) (}a) Peterson, M. L.; Vince, R. J. Med. Chem. 1991, 34, 2787. (b) Eva Ng, K.-m.; Orgel, L. E. J. Med. Chem. 1989, 32, 1754.
 (20) (a) Blackburn, G. M.; Eckstein, F.; Kent, D. E.; Perree, D.

Nucleosides Nucleotides 1985, 4, 165. (b) Bamford, M. J.; Coe, P. L.; Walker, R. T. J. Med. Chem. 1990, 33, 2488.

^{(21) (}a) Bergstrom, D. E.; Romo, E.; Shum, P. Nucleosides Nucleotides 1987, 6, 53. (b) Bergstrom, D. E.; Shum, P. W. J. Org. Chem. 1988, 53, 3953.

6




^a Reagent and conditions: (a) (i) SOCl₂, MeOH; (ii) NaBH₄, EtOH; (iii) TBDMSCl, DMAP, imidazole, CH₂Cl₂; (iv) t-Boc₂O, Et₃N, DMAP, CH₂Cl₂; (b) (i) LiHMDS, THF, -78 °C then PhSeCl, THF, -78 °C; (ii) H₂O₂, pyridine; (c) OsO₄, 4-methylmorpholine N-oxide monohydrate (NMNO), acetone-H₂O, rt; (d) BzCl, pyridine, DMAP, CH₂Cl₂, -78 then -10 °C; (e) Dess-Martin Oxidant, CH₂Cl₂, rt.

Thus, according to our retrosynthetic analysis, the lactam 2 was prepared from L-pyroglutamic acid over 4 steps in 42% yield (Scheme 2).27 Treatment of the compound 2 with LiHMDS/PhSeCl in THF at -78 °C followed by elimination of the resulting phenylselenyl derivative with H₂O₂/pyridine smoothly gave the alkene **3** in 75% yield.²⁸ Then, dihydroxylation of the compound 3 resulted in only isomer 4 in 62% yield along with recovery of 30% starting material.²⁹ Selective protection of the two hydroxyl groups of 4 with BzCl afforded the desired alcohol 5 in 85% yield and there are no other products detected by TLC except a few starting materials. Oxidation of the residual hydroxyl group in the compound 5 with the Dess-Martin oxidant was carried out; however, the reaction was very complicated and no expected compound 6 was isolated. In our opinion, the special structure of the desired compound **6** bearing a benzoylprotected hydroxy group between two keto groups was responsible for the failure of the reaction. The compounds containing this similar structure are unstable and prone to racemization and isomerization.³⁰

Synthesis of Target Molecules from trans-4-Hydroxy-L-proline. In view of the above failure, we changed our synthetic strategy; the new synthetic strategy is outlined in Scheme 3. In our opinion, the lactam skeleton of the intermediate **B** could be constructed via oxidation of the pyrrolidine \mathbf{F} , which might be prepared by difluoromethylenation of the keto G followed by hydrogenation. Similarly to the first route, dihydroxylation of the alkene I followed by selective protection of the resulting hydroxyl groups in H and oxidation of the residual hydroxyl group could provide the keto G. The intermediate I could be conveniently prepared from trans-4-hydroxy-proline 7.

Although the protective ester 8 was first prepared from trans-4-hydroxyproline 7 over three steps in 78% yield,³¹ treatment of the compound 8 with PhSeSePh/MeOH under reflux conditions following elimination of the



resulting phenylselenyl derivative smoothly afforded the alkene 9 in 63% yield over two steps.³² Then, reduction of the compound 9 with LiAlH₄ in Et₂O at room temperature gave the alcohol 10 in 89% yield. The protecting group for the primary hydroxy group was a key point because the diastereoselectivity of the following dihydroxylation was controlled by this protecting group. Thus, the big-blocking-effect protecting group, tert-butyldiphenylsilyl, was utilized and the favorable alkene 11 was provided in 82% yield. Dihydroxylation reaction was carried out on compound **11** and the only isomer **12** was obtained in 92% yield.

Selective protection of the hydroxyl groups in 12 was studied. According to the previous reports³³ and following transformation, the tert-butyldimethylsilyl group would be the appropriate protecting group. However, exposure of compound 12 to TBDMSCl/imidazole at 0 °C in DMF or CH₂Cl₂ only resulted in the recovery of the starting material, even when catalytic DMAP was added (Scheme 5). Increasing the reaction temperature to room temperature also gave the disappointing outcome and both the expected product 13 and the protective compound 14 were isolated in 31% and 49% yield, respectively. Slightly surprisingly, treatment of compound 12 with BzCl/ pyridine/DMAP at -10 °C for 24 h in CH₂Cl₂ gave the acceptable result and the favorable compound 15 was afforded in 70% yield along with isomer 16 in 17% yield and recovery of 7% starting material.

With compound 15 in hand, oxidation of the residual hydroxy group with Dess-Martin oxidant in CH₂Cl₂ at room temperature smoothly provided the keto **17** in 92% yield (Scheme 6). Then, difluoromethylenation of the carbonyl group with CF₂Br₂/Zn/HMPT in THF successfully afforded the fluorinated compound 18 in 83% yield.³⁴

⁽²⁶⁾ Altmann, K.-H. Tetrahedron Lett. 1993, 34, 7721.

^{(27) (}a) Ikota, N. Chem. Pharm. Bull. 1992, 40, 1925. (b) Pickering, L.; Malhi, B. S.; Coe, P. L.; Walker, R. T. Nucleosides Nucleotides 1994, 13, 1493.

⁽²⁸⁾ Frieman, B. A.; Bock, C. W.; Bhat, K. L. Heterocycles 2001, 55, 2099.

⁽²⁹⁾ Yoda, H.; Oguchi, T.; Takabe, K. T. Tetrahedron: Asymmetry 1996, 7, 2113.

^{(30) (}a) Roush, W. R.; Pfeifer, L. A. Org. Lett. 2000, 2, 859. (b) Jones, R. C. F.; Begley, M. J.; Peterson, G. E.; Sumaria, S. J. Chem. Soc., Perkin Trans. 1 1990, 1959.


^{(31) (}a) Greenwood, E. S.; Hitchcock, P. B.; Parsons, P. J. Tetrahedron 2003, 59, 3307

^{(32) (}a) Goli, D. M.; Cheesman, B. V.; Hassan, M. E.; Lodaya, R.; Slama, J. T. Carbohydr. Res. 1994, 259, 219. (b) Rueger, H.; Benn, M. H. Can. J. Chem. **1982**, 60, 2918. (c) Arakawa, Y.; Ohnishi, M.; Yoshimura, N.; Yoshifuji, S. Chem. Pharm. Bull. **2003**, 51, 1015. (d) Schumacher, K. K.; Jiang, J.; Joullié, M. M. Tetrahedron: Asymmetry 1998, 9, 47.

^{(33) (}a) Tokuda, M.; Fujita, H.; Miyamoto, T.; Suginome, H. Tetrahedron 1993, 49, 2413. (b) Iida, H.; Yamazaki, N.; Kibayashi, C. J. Org. Chem. 1986, 51, 1069. (c) Shi, S.-c.; Zeng, C.-m.; Lin, G.-q. Heterocycles 1995, 41, 277. (d) Kang, S. H.; Choi, H.-w. J. Chem. Soc., Chem. Commun. 1996, 1521. (e) Ikota, N.; Inaba, H. Chem. Pharm. Bull. 1996, 44, 587.


^{(34) (}a) Motherwell, W. B.; Tozer, M. J.; Ross, B. C. J. Chem. Soc., Chem. Commun. 1989, 1437. (b) Houlton, J. S.; Motherwell, W. B.; Ross, B. C.; Tozer, M. J.; Williams, D. J.; Slawin, A. M. Tetrahedron 1993, 49, 8087.

SCHEME 4^a




^a Reagent and conditions: (a) (i) SOCl₂, MeOH, 0 °C to room temperature; (ii) Boc₂O, CH₂Cl₂, Et₃N, DMAP, rt; (iii) MsCl, Et₃N, DMAP, CH₂Cl₂, rt; (b) (i) PhSeSePh, MeOH, reflux; (ii) H₂O₂, pyridine, rt.; (c) LiAlH₄, Et₂O, rt; (d) TBDPSCl, imidazole, DMAP, CH₂Cl₂, rt; (e) OsO₄, 4-methylmorpholine *N*-oxide monohydrate (NMNO), acetone-H₂O, rt.

SCHEME 5^a



 a Reagent and conditions: (a) TBDMSCl, DMAP, imidazole, DMF, rt, 3 h; (b) BzCl, pyridine, CH_2Cl_2, -10 °C, 24 h.

SCHEME 6^a



 a Reagent and conditions: (a) Dess–Martin oxidant, CH_2Cl_2, rt; (b) CF_2Br_2, HMPT, Zn, THF, reflux.

Although hydrogenations of similar substrates were reported,³⁵ hydrogenation of alkene **18** was still a challenge to us due to bulky block effects of the neighboring groups. Thus, different solvents, catalysts, and hydrogen pressure were used to investigate the hydrogenation reaction (Table 1). Pd/C was first selected as catalyst (entries 1–5). Hydrogenation of **18** in MeOH at room temperature and 1 atm (H₂) for 17 h gave a disappointing outcome and the desired compounds **19** and **20** were isolated in 11% and <1% yield, respectively, along with recovery of 9% starting material (entry 1). The low yield was attributed to the decomposition of **18** under proton solvent. However, there was no reaction that occurred

TABLE 1. Hydrogenation of Compound 18

		pressure		time	yield (%)		recovery
entry	catalyst	(atm)	$\operatorname{solvent}$	(h)	19	20	(%)
1	10% Pd/C	1	MeOH	17	11	<1	9
2	10% Pd/C	1	EtOAc	24	0	0	83
3	10% Pd/C	20	EtOAc	24	31	<1	46
4	10% Pd/C	70	EtOAc	17	41	12	9
5	10% Pd/C	80	THF	17	27	7	38
6	Pd(OH) ₂ /C	80	THF	7	<1	<1	87
7	Pd(OH) ₂ /C	80	EtOAc	7	13	20	48
8	Pd(OH) ₂ /C	80	dioxane	7	<4	13	77
9	Pd(OH) ₂ /C	80	dioxane	65	<4	48	37
10	Pd(OH) ₂ /C	100	dioxane	31	10	54	22


with substitution of EtOAc for MeOH under the same conditions (entry 2). Thus, 20 atm of H_2 was used for this reaction and after 24 h, compound 19 was afforded in 31% yield besides a small amount of compound 20 and 46% recovery of 18 (entry 3). When the hydrogen pressure was increased to 70 atm, the yield of 19 was increased to 41%. However, the decomposition was also obvious with only 9% recovery of 18 (entry 4). The replacement of EtOAc with THF did not give a better hydrogenation outcome (entry 5). Pd(OH)₂/C was also used as a catalyst to investigate this reaction (entries 6-10). Using THF as a solvent under 80 atm of H_2 also gave a bad result (entry 6). Besides 48% recovery of starting material, compounds 19 and 20 were provided in 13% and 20% vield, respectively, with utilization of EtOAc as solvent (entry 7). When the reaction was carried out under 80 atm of H₂ with dioxane as solvent, the main compound 20 was afforded in 13% yield after 7 h (entry 8). Prolongation of reaction time to 65 h could increase the yield of 20 to 48% (entry 9). Finally, when the hydrogen pressure was added to 100 atm also with dioxane as solvent, compounds 19 and 20 were furnished in 10% and 54% yield, respectively (entry 10). It was evident from the above hydrogenation outcome that pressure and solvent were two important points to the hydrogenation of 18. Also obvious was that the catalysts Pd/C and Pd(OH)₂/C could give different stereoselectivity. That was, diasteroisomer 19 was the main product with Pd/C being used, and diastersoisomer 20 was provided as the main product with Pd(OH)₂/C as catalyst. In our opinion, when Pd/C was used, the blocking effect of the substrate induced the attack of hydrogen on the Re side of the double bound, which resulted in the main product 19. However, hydrogen mainly attacked the Si side to afford the main product 20 with $Pd(OH)_2/C$ as catalyst, perhaps due to the influence of the hydrogen bond between the hydroxy group and the oxygen atoms of substrate.

Then, oxidation of compounds **19** and **20** with RuO_2 · $x\text{H}_2\text{O}/\text{NaIO}_4$ under ethyl acetate/water biphase condition was carried out, respectively (Scheme 7). However, the reactions were complicated and only a few expected compounds were detected by TLC. Although many successful examples about the oxidation of the pyrrolidine substrates containing silyl group(s) to the corresponding lactams with RuO_2 · $x\text{H}_2\text{O}/\text{NaIO}_4$ were reported, Young et al.³⁶ reported that the *tert*-butyldiphenylsilyl group could be oxidated to the *tert*-butylhydroxylphenylsilyl group by

^{(35) (}a) Serafinowski, P. J.; Brown, C. A.; Barnes, C. L. *Nucleosides Nucleotides* **2001**, *20*, 921. (b) Marcotte, S.; Gerard, B.; Pannecoucke, X.; Feasson, C.; Quirion, J.-C. *Synthesis* **2001**, 929.


^{(36) (}a) Durand, X.; Hudhomme, P.; Khan, J. A.; Young, D. W. J. Chem. Soc., Perkin Trans. 1 **1996**, 1131. (b) Durand, X.; Hudhomme, P.; Khan, J. A.; Young, D. W. Tetrahedron Lett. **1995**, 36, 1351.

SCHEME 7^a



 a Reagent and conditions: (a) $RuO_2{\boldsymbol{\cdot}} xH_2O,$ NaIO4, EtOAc, H2O, rt.

SCHEME 8^a



^{*a*} Reagent and conditions: (a) (i) TBAF, THF, rt; (ii) TBDMSCl, imidazole, DMAP, CH₂Cl₂, rt; (b) (i) saturated NH₃/MeOH, rt; (ii) TBDMSCl, imidazole, DMAP, DMF, rt; (c) RuO₂·*x*H₂O, NaIO₄, EtOAc, H₂O, rt.

 $RuO_2 \cdot xH_2O/NaIO_4$. While no *tert*-butylhydroxylphenylsilyl-containing compound was isolated, it is our opinion that the failures of the reactions were attributed to the existence of the *tert*-butyldiphenylsilyl group.

In view of the above failure and following transformation, we decided to replace the protecting groups of hydroxy groups with tert-butyldimethylsilyl groups. Thus, exposure of compound 20 to TBAF in THF followed by protection of the resultant primary hydroxyl group with the tert-butyldimethylsilyl group provided compound 21 in 75% yield over two steps (Scheme 8). The absolute configuration of compound 21 was confirmed by X-ray. Then, treatment of 21 with a saturated solution of ammonia in methanol followed by protection of the resultant hydroxyl group also with the tert-butyldimethvlsilyl group smoothly afforded compound 23 in 86% yield. Similarly, compound 22 was furnished from 19 in 60% yield over four steps. Next oxidation of the pyrrolidine 22 with RuO₂·xH₂O/NaIO₄ under ethyl acetate/water biphase condition was carried out and the desired lactam 24 was provided in 40% yield after 16 h. However, tertiary alcohol 26 was also isolated in 33% yield, which resulted from the oxidation of the hydrogen atom in the 2'-C position of compound **22**, just as reported by Ikota.³⁷ Treatment of compound 23 with the same condition for 13.5 h gave the desired compound **25** and alcohol **27** in 54% and 2% yield, respectively, along with the 11%recovery of starting material. Obviously from the yield of alcohols 26 and 27, besides the electron effect,³⁸ the RuO₄ oxidation procedure was also influenced by the blocking effect. That is, the hydrogen atom in the 2'-C position of compound 23 is more efficiently shielded than that of compound 22, which directly resulted in the lower yield of the byproduct 27 than that of 26.

Lactam **24** was reduced by LiBEt₃H in anhydrous THF to provide exclusively β -anomeric isomer, which was then

treated with acetic anhydride to afford anomeric acetate 28 in 95% yield over two steps (Scheme 9). Similarly, lactam 25 was transformated predominantly, but not exclusively, into anomeric acetate 29a (55%) and 29b (11%) under the same conditions. Coupling of 28 with silylated uracil under Vorbrüggen conditions³⁹ gave mainly the α -anomer **30b** in 67% yield along with the β -anomer **30a** in 7% yield. Silyl-protected azanucleosides 30a and 30b could be separated by column chromatography. However, acetate 29a was condensed with silylated uracil, as described for **28**, to afford mainly β -anomer **31a** in 77% yield along with the α -anomer **31b** in 13% yield. Coupling of acetate **29a** with silvlated thymine gave β -anomer **32a** and α -anomer **32b** in 49% and 31% yield, respectively. Finally, removal of the silvl protective groups with TBAF in THF smoothly gave 3'-deoxy-3'difluoromethyl azanucleosides 33, 34a, 34b, and 35. The opposite stereochemical outcome in coupling acetate 28 and 29a with silvlated uracil could be elucidated from Figure 1. That is, the silvlated uracil mainly attacked the less shielded Re side of the double bond in intermediate 28', which resulted in the formation of α -anomer 30b. However, the Si diastereoface of intermediate 29' was less shielded, which was mainly subjected to the attack of silvlated uracil to provide β -anomer **31a** as the main product.

The stereochemical assignments of the silylated azanucleosides were made on the base of 1D and 2D NMR spectroscopy and X-ray crystallography. The configuration of the anomeric center was assigned mainly by ¹H NMR, in which the anomers with H4' at lower field were assigned as the α -anomers and the ones at higher field were assigned as the β -anomers on the base of the deshielding effect of the base moiety (Figure 2).⁴⁰ This assignment was further confirmed by the NOESY experiment of **30a**, **30b**, **31a**, and **31b** (Figure 2) as well as the X-ray crystallography of **30a**.

In summary, two strategies were used to synthesize 3'-deoxy-3'-difluoromethyl azanucleosides. After the failure of the first route, we stereoselectively prepared the key intermediate 12 from trans-4-hydroxy-proline 7 in eight steps. Alcohol 12 was subjected to selective protection, oxidation, and difluoromethylenation to afford the fluorinated compound 18, whose hydrogenation was then systematically investigated. After a series of transformations of protecting groups, the resultant compounds 22 and 23 were oxidized to the desired lactams 24 and 25, which were successfully utilized to synthesize our target molecules, 3'-deoxy-3'-difluoromethyl azanucleosides 33, 34a, 34b, and 35. Furthermore, work is in progress to use the intermediates 24 and 25 for the synthesis of other biologically potential active compounds. Antiviral and cytotoxicity evaluations of compounds 33, 34a, 34b, and 35 are also currently in progress.


Experimental Section

THF was distilled from sodium metal. CH_2Cl_2 and pyridine were distilled from CaH_2 . All the melting points and optical rotations are uncorrected. Chemical shifts (δ) of ¹H NMR, ¹³C

⁽³⁸⁾ Lee, D. G.; Van den Engh, M. Can. J. Chem. 1972, 50, 3129.
(39) (a) Vorbrüggen, H.; Krolikiewicz, K.; Bennua, B. Chem. Ber. 1981, 114, 1234. (b) Vorbrüggen, H.; Höfle, G. Chem. Ber. 1981, 114, 1256.

⁽⁴⁰⁾ Chun, B. K.; Olgen, S.; Hong, J. H.; Newton, M. C.; Chu, C. K. J. Org. Chem. **2000**, *65*, 685.

SCHEME 9^a



^{*a*} Reagent and conditions: (a) (i) LiBEt₃H, THF, -78 °C; (ii) Ac₂O, CH₂Cl₂, Et₃N, DMAP, rt; (b) silylated uracil or thymine, *N*,*O*-bis(trimethylsilyl)acetamide, TMSOTf, 0 °C to rt. (c) TBAF, THF, rt.




FIGURE 1. Explanation of the opposite stereochemical outcome in the glycosylation reaction.




FIGURE 2. Selective NOE correlation from NOESY spectra of 30a, 30b, 31a, and 31b and ¹H NMR data of H4'.

NMR, and ¹⁹F NMR (CFCl₃ as external standard and low field is positive) spectra are reported in ppm, and coupling constants (J) are in Hz.

Compounds ${f 2}$ and ${f 3}$ were prepared according to the literature procedure. 27,28

(3R,4R,5R)-*N-tert*-Butoxycarbonyl-3,4-dihydroxy-5-(*tert*-butyldimethylsiloxymethyl)pyrrolidin-2-one (4). To a cooled solution of compound 3 (323 mg, 0.98 mmol) and 4-methylmorpholine *N*-oxide monohydrate (NMNO) (222 mg, 1.49 mmol) in acetone (15 mL) and H₂O (4 mL) was added OsO₄ (0.50 mL, 0.1 M in toluene, 0.05 mmol) dropwise. The

resulting mixture was stirred at room temperature for 4 days. The reaction was guenched with H₂O and the mixture was extracted with CH_2Cl_2 (3 \times 30 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 2:3) to afford 4 as a white solid (219 mg, 62%) and the starting material (95 mg). Compound 4: mp 74-76 °C; [a]²⁰_D -10.6 (c 0.84, CHCl₃); ¹H NMR (300 MHz, $CDCl_3$) δ 4.58 (d, J = 4.8 Hz, 1H), 4.32 (d, J = 4.8 Hz, 1H), 4.09 (br, 1H), 3.94 (dd, J = 3.0, 2.4 Hz, 1H), 3.80 (d, J = 10.2Hz, 2H), 3.39 (br, 1H), 1.50 (s, 9H), 0.83 (s, 9H), 0.01, -0.01 (2s, 6H); $^{13}\mathrm{C}$ NMR (75.5 MHz, CDCl_3) δ 173.9, 149.7, 83.6, 71.6, 69.3, 64.7, 61.8, 28.0, 25.8, 18.2, -5.6; IR (thin film) 3440, 2957, 1776, 1739, 1695, 1473, 1367, 1286 cm⁻¹; MS (ESI) m/z 384.2 $(M + Na^{+})$. Anal. Calcd for $C_{16}H_{31}NO_{6}Si: C, 53.18; H, 8.59;$ N, 3.88. Found: C, 53.20; H, 8.53; N, 3.67.

(3R,4R,5R)-N-tert-Butoxycarbonyl-3-benzoyloxy-4-hydroxy-5-(tert-butyldimethylsiloxymethyl)pyrrolidin-2one (5). To a solution of compound 4 (213 mg, 0.59 mmol) and DMAP (6 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) and pyridine (2 mL) at -78 °C was added BzCl (71 μ L, 0.61 mmol) dropwise. The mixture was then warmed to -10 °C and stirred for 12 h. The reaction was quenched with H₂O (5 mL) and the resulting mixture was extracted with CH_2Cl_2 (3 \times 25 mL). The combined organic phases were washed with 1 M citric acid and brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 4:1) to afford 5 as a oil (235 mg, 85%) and the starting material (8 mg). Compound 5: $[\alpha]^{20}$ _D -32.3 (*c* 0.78, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.10 (d, $J=8.4~{\rm Hz},\,2{\rm H}),\,7.59$ (t, $J=7.5~{\rm Hz},\,1{\rm H}),\,7.44$ (t, J=7.5 Hz, 1H), 5.92 (d, J = 5.4 Hz, 1H), 4.57 (d, J = 5.4 Hz, 1H), 4.19 (s, 1H), 4.04 (dd, J = 2.7, 2.4 Hz, 1H), 3.86 (d, J = 10.8Hz, 1H), 2.66 (br, 1H), 1.54 (s, 9H), 0.90 (s, 9H), 0.08, 0.06 (2s, 6H); ¹³C NMR (75.5 MHz, CDCl₃) δ 168.2, 165.2, 149.9, 133.6, $130.1,\,128.8,\,128.5,\,83.6,\,72.8,\,69.1,\,64.9,\,61.7,\,28.0,\,25.8,\,18.6,$ -5.6; IR (thin film) 3486, 2957, 1789, 1728, 1603, 1473, 1371, 1309, 1258, 838 cm⁻¹; MS (ESI) m/z 488.3 (M + Na⁺); ESI-HRMS m/z 488.2072 (M + Na⁺, C₂₃H₃₅NO₇Si required 488.2075).

(4*R*)-*N*-tert-Butoxycarbonyl-4-methylsulfonyloxy-l-proline Methyl Ester (8). To a cooled solution of *trans*-4-hydroxy-

L-proline 7 (10.00 g, 76.26 mmol) in anhydrous MeOH (100 mL) was added $SOCl_2$ (6.5 mL, 89.06 mmol) dropwise. After the mixture was refluxed for 2 h, it was cooled to room temperature and stirred overnight. After the solvent was removed in vacuo, the residue was washed twice with anhydrous Et_2O to provide white solid (14.00 g). Then, to a cooled solution of the above white solid (14.00 g) and DMAP (2.00 g, 16.39 mmol) in anhydrous CH₂Cl₂ (150 mL) was added Et₃N (25 mL), followed by a solution of Boc₂O (19.0 mL, 88.79 mmol) in CH₂Cl₂ (50 mL) dropwise. The mixture was warmed to room temperature and stirred overnight. The reaction was quenched with H₂O and the aqueous layer was extracted with CH₂Cl₂. The combined organic phases were washed with 1 M citric acid and brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 1:1) to afford a white solid (15.529 g), which was then solved in CH_2Cl_2 (250 mL). After the miture was cooled to 0 °C, DMAP (2.00 g, 16.39 mmol) and Et₃N (13 mL) were added, followed by MsCl (7.3 mL, 94.32 mmol) dropwise. The mixture was stirred for 2 h and H₂O (50 mL) was added. The aqueous layer was extracted with CH₂Cl₂. Then, the combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 2:1) to afford **8** as a white solid (19.317 g, 78%). $[\alpha]^{25}$ _D -48.4 (*c* 1.58, CHCl₃) (lit.³¹ [α]²⁵_D -50.7 (*c* 1.5 CHCl₃)); ¹H NMR (300 MHz, CDCl₃) δ 5.26 (br, 1H), 4.47–4.37 (m, 1H), 3.86–3.75 (m, 1H), 3.82 (s, 3H), 3.08 (s, 3H), 2.68–2.55 (m, 1H), 2.32–2.23 (m, 1H), 1.47, 1.42 (2s, 9H); MS (ESI) m/z 346.1 (M + Na⁺).

Methyl (2S)-N-tert-Butyloxycarbonyl-3,4-dehydroprolinate (9). To a 0 °C solution of 8 (19.317 g, 59.80 mmol) and PhSeSePh (11.222 g, 35.95 mmol) in MeOH (450 mL) was added NaBH₄ (3.0 g, 78.95 mmol) in several portions. Then, the mixture was refluxed about 11 h and the solution was removed in vacuo. H₂O (100 mL) was added and the mixture was extracted with Et_2O (3 \times 80 mL). The combined organic was washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 2:1) to afford an oil (20.213 g), which was then resolved in CH₂Cl₂ (320 mL) and pyridine (6.5 mL) and 30% aqueous H_2O_2 (15 mL) were added. After about 2 h, H_2O (100 mL) was added. The organic layer was then washed with 1 M citric acid, saturated aqueous Na₂SO₃, and brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 10:1) to afford 9 as a clear oil (8.57 g, 63%). $[\alpha]^{20}_{D}$ -261.0 (c 1.11, CHCl₃) (lit.^{32d} $[\alpha]^{20}_{D}$ -131.0 (c 1.22, CHCl₃)); ¹H NMR (300 MHz, CDCl₃) & 5.98-5.95 (m, 1H), 5.69-5.66 (m, 1H), 4.94-4.91 (m, 1H), 4.25-4.15 (m, 2H), 3.71, 3.70 (2s, 3H), 1.45, 1.39 (2s, 9H), rotamers; ¹³C NMR (75.5 MHz, CDCl₃) δ 170.9 and 170.6, 153.8 and 153.3, 129.3 and 129.2, 124.7 and 124.6, 80.1, 66.5 and 66.2, 53.4 and 53.2, 52.1, 52.0 and 51.9, 28.3 and 28.2, rotamers.

(2S)-*N*-tert-Butyloxycarbonyl-2-hydroxymethyl-3-pyrroline (10). To a 0 °C solution of 9 (8.57 g, 37.75 mmol) in anhydrous Et₂O (200 mL) was added LiAlH₄ (1.55 g, 41.2 mmol). The mixture was then warmed to room temperature and stirred for 1 h. The reaction was quenched with H₂O (50 mL) and the aqueous layer was extracted with Et₂O (3×50 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 3:1 then 2:1) to afford 10 as a clear oil (6.72 g, 89%). [α]²⁰_D -107.8 (c 1.23, CHCl₃) (lit.³¹ [α]²⁰_D -107.2 (c 13.9, CHCl₃)); ¹H NMR (300 MHz, CDCl₃) δ 5.84 (br, 1H), 5.65 (br, 1H), 4.72 (br, 1H), 4.22-4.04 (m, 3H), 3.79-3.75 (dd, J = 2.7, 2.4 Hz, 1H), 3.62-3.60 (br, 1H), 1.51, 1.49 (2s, 9H), rotamers.

(2S)-N-tert-Butyloxycarbonyl-2-(tert-butyldiphenylsiloxymethyl)-3,4-dehydropyrrolidine (11). To a 0 °C solution of 10 (6.72 g, 33.77 mmol) and imidazole (6.88 g, 101.18 mmol) in CH₂Cl₂ (130 mL) was added DMAP (420 mg, 3.44 mmol), followed by TBDPSCl (14 mL, 53.48 mmol) dropwise. The mixture was then stirred overnight and the reaction was quenched with H_2O (50 mL). The aqueous layer was extracted with CH_2Cl_2 (3 × 20 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 15:1) to afford 11 as a white foam (12.10 g, 82%). $[\alpha]^{20}{}_D$ –90.1 (c 1.06, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.66-7.64 (m, 4H), 7.39-7.37 (m, 6H), 5.89-5.78 (m, 2H), 4.64-4.52 (2br, 1H), 4.29–3.99 (m, 2.4H), 3.85 (ddd, J = 16.7, 3.0, 2.9 Hz, 1H), $3.69 \,(dd, J = 6.3, 6.6 \,Hz, 0.6H), 1.48, 1.36 \,(2s, 9H), 1.00 \,(s, 3.69 \,H), 1.00 \,H), 1.00 \,(s, 3.69 \,H), 1.00 \,(s, 3.69 \,H), 1.00 \,(s, 3.69 \,$ 9H), rotamers; ¹³C NMR (75.5 MHz, CDCl₃) δ 154.0, 135.6, 129.6, 129.5, 128.7, 127.6, 126.2, 79.3 and 79.1, 65.5 and 65.3, 65.1, 63.7, 54.2 and 54.0, 28.5 and 28.4, 26.7, 19.3, 19.2, rotamers; IR (thin film) 3073, 3051, 2860, 1960, 1741, 1701, 1627, 1590, 1402, 1114, 702 cm⁻¹; MS (ESI) m/z 438.3 (M + H⁺); ESI-HRMS m/z 438.2460 (M + H⁺, C₂₆H₃₆NO₃Si required 438.2459).

(2R,3R,4S)-N-tert-Butyloxycarbonyl-3,4-dihydroxy-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (12). To a 0 °C solution of 11 (10.00 g, 22.88 mmol) and 4-methylmorpholine N-oxide monohydrate (NMNO) (9.10 g, 67.41 mmol) in acetone (250 mL) and H₂O (60 mL) was added OsO₄ (5.0 mL, 0.1 M in toluene, 0.5 mmol). The resulting mixture was warmed to room temperature and stirred for 5 h. Then, Na_2SO_3 (5.0 g) was added and after 30 min of stirring, the mixture was extracted with EtOAc (3 \times 100 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 1:1) to afford 12 as a white foam (9.65 g, 92%). [α]²⁰_D -30.5 (*c* 1.01, MeOH); ¹H NMR (300 MHz, MeOH-d₄) & 7.64-7.61 (m, 4H), 7.42-7.35 (m, 6H), 4.40-4.30 (m, 2H), 4.08 (dd, J = 3.9, 3.6 Hz, 0.48H), 3.88 (dd, J = 4.2, 4.5 Hz, 0.62 H), 3.77 - 3.66 (m, 2H), 3.59 - 3.39 (m, 2H),1.47, 1.28 (2s, 9H), 1.03, 1.02 (2s, 9H), rotamers; ¹³C NMR (75.5 MHz, MeOH- $d_4)$ δ 156.4, 136.6, 135.7, 135.6, 134.5, 134.4, 134.3, 131.0, 128.9, 81.1 and 80.9, 75.0 and 74.5, 71.3 and 70.8, 66.3 and 66.0, 63.8 and 63.0, 52.8 and 52.1, 28.9 and 28.8, 27.4, 20.1, rotamers; IR (thin film) 3395, 3073, 3051, 2932, 1698, 1670, 1590, 1427, 1113, 702 cm⁻¹; MS (ESI) m/z 472.3 (M + H⁺); ESI-HRMS m/z 494.2322 (M + Na⁺, C₂₆H₃₇NO₅NaSi required 494.2333).

(2R, 3R, 4S) - N - tert - Butyloxy carbonyl - 4 - tert - butyldi methylsilyloxy-3-hydroxy-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (13) and (2R,3R,4S)-N-tert-Butyloxycarbonyl-4-tert-butyldimethylsilyloxy-3-tert-butyldimethylsilyloxy-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (14). To a 0 °C solution of 12 (90 mg, 0.19 mmol) and DMAP (3 mg, 0.02 mmol) in DMF (0.5 $\rm m\bar{L})$ was added imidazole (68 mg, 0.49 mmol), followed by TBDMSCl (32 mg, 0.21 mmol). Then, the mixture was warmed to room temperature and stirred for 3 h. EtOAc (40 mL) was added and the resulting mixture was washed with brine $(3 \times 15 \text{ mL})$. The organic phase was dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 10:1) to afford 13 as a white foam (35 mg, more polar, 31%) and 14 as a white foam (65 mg, less polar, 49%). Compound 13: [α]²⁴_D –12.4 (*c* 1.32, acetone); ¹H NMR (300 MHz, acetone d_6) δ 7.70–7.68 (m, 4H), 7.46–7.42 (m, 6H), 4.60–4.55 (m, 1H), $4.33-4.29 \ (m, \ 1H), \ 4.12-3.88 \ (m, \ 1H), \ 3.84-3.71 \ (m, \ 2H),$ 3.64-3.52 (m, 1H), 3.47-3.35 (m, 2H), 1.47, 1.32 (2s, 9H), 1.07 (s, 9H), 0.93 (s, 9H), 0.15, 0.14 (2s, 6H), rotamers; ¹³C NMR $(75.5 \text{ MHz}, \text{ acetone-}d_6) \delta 155.4 \text{ and } 155.2, 136.6, 136.5, 135.6,$ 134.6, 134.5, 134.4, 130.9, 128.9, 79.7, 75.5 and 74.9, 72.8 and 72.3, 66.2 and 66.1, 64.4 and 63.5, 52.8 and 52.4, 29.0 and 28.9, 27.6, 26.5, 20.1, 19.0, -4.3, rotamers; IR (thin film) 3439, 3073, 3053, 2956, 1699, 1681, 1590, 1409, 1113, 838 cm⁻¹; MS (ESI)

m/z 608.3 (M + Na⁺), 586.3 (M + H⁺); ESI-HRMS m/z 586.3375 (M + H⁺, C₃₂H₅₂NO₅Si₂ required 586.3379). Compound **14**: $[\alpha]^{20}_{\rm D}$ – 5.5 (c 2.33, acetone); $^1{\rm H}$ NMR (300 MHz, acetone- d_6) δ 7.73–7.70 (m, 4H), 7.45–7.42 (m, 6H), 4.45–4.39 (m, 2H), 3.95–3.76 (m, 3H), 3.51–3.34 (m, 2H), 1.45, 1.32 (2s, 9H), 1.08 (s, 9H), 0.92, 0.91 (2s, 18H), 0.17–0.12 (m, 12H), rotamers; $^{13}{\rm C}$ NMR (75.5 MHz, acetone- d_6) δ 155.6 and 155.3, 136.4, 135.5, 134.4, 134.2, 134.0, 130.9, 130.8, 128.9, 128.8, 128.7, 79.6, 75.8 and 75.3, 72.5 and 72.0, 67.1 and 66.8, 63.9 and 63.1, 28.8, 28.7, 27.5, 26.5, 26.4, 20.0 and 19.9, 18.9, –3.8, –4.4, –4.2, –4.2, –4.3, rotamers; IR (thin film) 2957, 2859, 1702, 1473, 1393, 1254, 1113, 837 cm⁻¹; MS (ESI) m/z 722.5 (M + Na⁺), 700.5 (M + H⁺); ESI-HRMS m/z 700.4245 (M + H⁺, C₃₈H₆₆NO₅Si₃ required 700.4243).

(2R,3R,4S)-N-tert-Butyloxycarbonyl-4-benzoyloxy-3hydroxy-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (15) and (2R,3R,4S)-N-tert-Butyloxycarbonyl-4-hydroxy-3-benzoyloxy-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (16). To a -78 °C solution of 12 (716 mg, 1.52 mmol) and DMAP (10 mg, 0.08 mmol) in $CH_2Cl_2\,(4.5$ mL) was added pyridine (3.0 mL), followed by BzCl (176 μ L, 1.52 mmol) dropwise. Then, the mixture was warmed to -10°C and stirred for 24 h. The reaction was quenched with H₂O (10 mL) and the aqueous layer was extracted with CH₂Cl₂ (3 imes 30 mL). The combined organic phases were washed with 1 M citric acid and brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 8:1) to afford 15 as a white foam (614 mg, less polar, 70%) and 16 as a white foam (145 mg, more polar, $17\bar{\varnothing})$ and the starting material (52 mg, 7%). Coumpound 15: $[\alpha]^{20}$ -26.3 (c 0.94, acetone); ¹H NMR (300 MHz, acetone-*d*₆) δ 8.11–7.44 (m, 15H), 5.67-5.62 (m, 1H), 4.85-4.71 (m, 2H), 4.19-3.96 (m, 1H), 3.90-3.69 (m, 4H), 1.49-1.34 (m, 9H), 1.09, 1.08 (2s, 9H), rotamers; $^{13}\mathrm{C}$ NMR (75.5 MHz, acetone- $d_6)$ δ 166.6, 155.2, 136.5, 134.1, 131.4, 130.8, 130.6, 129.5, 128.9, 79.9, 74.5 and 74.2, 73.5 and 72.9, 66.5 and 66.3, 64.0 and 63.1, 50.1 and 49.7, 28.9, 27.5, 20.0, rotamers; IR (thin film) 3434, 3073, 2933, 1964, 1725, 1699, 1677, 1603, 1589, 1275, 1114, 709 cm⁻¹; MS (ESI) m/z 598.2 (M + Na⁺), 576.2 (M + H⁺); ESI-HRMS m/z598.2575 (M + Na⁺, $C_{33}H_{41}NO_6NaSi$ required 598.2595). Compound 16: $[\alpha]^{20}_{D} - 16.0$ (c 0.57, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 8.09 (d, J = 7.8 Hz, 2H), 7.72–7.39 (m, 13H), 5.73-5.68 (m, 1H), 4.76 (br, 1H), 4.60-4.58 (m, 1H), 4.21-3.85 (m, 3H), 3.77-3.55 (m, 2H), 1.49, 1.31 (2s, 9H), 1.05 (s, 9H), rotamers; ¹³C NMR (75.5 MHz, acetone- d_6) δ 166.6, 155.2 and 154.9, 136.5, 134.1, 131.5, 130.9, 130.7, 129.5, 128.9, 79.9, 77.8 and 77.2, 70.1 and 69.5, 64.1 and 63.1, 63.6, 53.0 and 52.6, 28.8, 27.5, 20.0, rotamers; IR (thin film) 3441, 3073, 2933, 1725, 1699, 1679, 1603, 1589, 1473, 1276, 1114, 709 cm⁻¹; MS (ESI) *m/z* 576.3 (M + H⁺); ESI-HRMS *m/z* 598.2584 $(M + Na^{+}, C_{33}H_{41}NO_6NaSi required 598.2596)$

(2R,4S)-N-tert-Butyloxycarbonyl-4-benzoyloxy-3-oxo-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (17). To a cooled solution of Dess-Martin oxidant (618 mg, 1.46 mmol) in CH₂Cl₂ (6 mL) was added a solution of **15** (536 mg, 0.93 mmol) in CH₂Cl₂ (12 mL) dropwise. The mixture was warmed to room temperature and stirred for 1.5 h. Then, the mixture was cooled again and a solution of Na₂S₂O₄ (1.0 g) and NaHCO₃ (200 mg) in H₂O (10 mL) was added dropwise. The resulting mixture was stirred for about 0.5 h and the aqueous layer was extracted with CH_2Cl_2 (3 \times 30 mL). The combined organic phases were washed with saturated aqueous NaHCO3 and brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 10:1) to afford 17 as a white foam (489 mg, 92%). $[\alpha]^{20}D$ -30.8 (c 1.2, acetone); ¹H NMR (300 MHz, acetone-d₆) δ 8.11-8.07 (m, 2H), 7.72-7.66 (m, 5H), 7.58-7.44 (m, 8H), 5.67 (dd, J = 7.5, 7.8 Hz, 1H), 4.48-4.18 (m, 3H), 3.96 (t, J = 10.2 Hz, 1H), 3.82 (t, J =8.9 Hz, 1H), 1.55, 1.38 (2s, 9H), 1.07 (s, 9H); ¹³C NMR (75.5 MHz, acetone- d_6) δ 207.3, 166.1, 155.0, 136.5, 134.8, 133.7, 131.1, 130.8, 130.1, 129.8, 129.0, 81.0, 74.0, 65.0, 64.2, 48.8, 28.8, 27.4, 20.0; IR (thin film) 3073, 2933, 1780, 1731, 1702, 1602, 1589, 1396, 1273, 1115, 709 cm⁻¹; MS (ESI) m/z 574.3 (M + H⁺); ESI-HRMS m/z 596.2426 (M + Na⁺, C₃₃H₃₉NO₆NaSi required 596.2439).

(2S,4R)-N-tert-Butyloxycarbonyl-4-benzoyloxy-3-difluoromethylenyl-2-(tert-butyldiphenylsiloxymethyl)**pyrrolidine (18).** To a -15 °C solution of **17** (2.149 g, 3.75 mmol) in THF (80 mL) was added HMPT (3.5 mL, 18.5 mmol) followed by CF₂Br₂ (1.75 mL, 19.10 mmol). The mixture was stirred at room temperature for 0.5 h and then Zn dust (1.20 g, 18.5 mmol) was added. The mixture was heated to reflux for 0.5 h and cooled to room temperature. H_2O (50 mL) and Et_2O (100 mL) were added. The aqueous phase was extracted with Et_2O (3 × 30 mL). The combined organic phases were washed with saturated aqueous CuSO₄ and brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 25:1) to afford 18 as a white foam (1.886 g, 83%). [α]^{20} $_{D}$ +22.4 (c 1.0, acetone); ^1H NMR (300 MHz, acetone- d_6) δ 8.04 (d, J = 7.5 Hz, 2H), 7.70-7.64 (m, 5H), 7.55-7.46 (m, 8H), 6.22 (br, 1H), 4.90 (br, 1H), 4.24-3.92 (m, 3H), 3.79 (t, J = 12.5 Hz, 1H), 1.47, 1.40 (2s, 9H),1.08 (s, 9H), rotamers; ¹⁹F NMR (282 MHz, CDCl₃) δ -84.17 to -84.38 (m, 1F), -84.64 to -84.89 (m, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) δ 166.5, 154.5 and 154.1, 153.3 (t, J = 290.1Hz) and 153.2 (t, J = 288.8 Hz), 136.5, 136.4, 134.5, 131.1, 131.0, 130.6, 129.7, 129.0, 92.6 (t, J = 21.2 Hz) and 91.9 (t, J= 21.0 Hz), 80.7, 72.6 (d, J = 6.6 Hz) and 72.0 (d, J = 4.8 Hz), 65.3 and 64.2, 59.3, 55.1 and 54.6, 28.8, 27.4, 20.0, rotamers; IR (thin film) 3073, 2933, 1961, 1772, 1724, 1702, 1602, 1580, 1474, 1403, 1278, 1265, 1174, 1106, 710 cm⁻¹; MS (ESI) m/z630.2 (M + Na⁺), 608.2 (M + H⁺); ESI-HRMS m/z 630.2453 $(M + Na^+, C_{34}H_{39}F_2NO_5NaSi required 630.2458).$

(2S,3S,4R)-N-tert-Butyloxycarbonyl-4-benzoyloxy-3-difluoromethyl-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (19) and (2S,3R,4R)-N-tert-Butyloxycarbonyl-4benzoyloxy-3-difluoromethyl-2-(tert-butyldiphenylsiloxymethyl)pyrrolidine (20). Typical procedure: To a solution of 18 in solvent was added catalyst. Then, the mixture was hydrogenated under different press. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 25:1) to afford 19 as a white foam (less polar) and 20 as a white foam (more polar). Compound **19**: $[\alpha]^{20}_{D}$ –11.0 (c 0.22, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 8.09-8.06 (m, 2H), 7.73-7.45 (m, 13H), 6.41 (tt, J = 55.7, 7.8 Hz, 1H), 6.10-6.04 (m, 1H), 4.29-4.16 (m, 2H), 4.12–3.98 (m, 1H), 3.72 (t, J = 12.9 Hz, 1H), 3.51 (dd, J = 6.3, 6.0 Hz, 1 H), 3.40 - 3.22 (m, 1H), 1.48, 1.32(2s, 9H), 1.13 (s, 9H), rotamers; $^{19}\mathrm{F}$ NMR (282 MHz, acetone d_6) $\delta - 114.12$ to -115.40 (m, 1F), -119.66 to -121.04 (ddd, J = 313.8, 18.0, 19.0 Hz, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) $\delta \ 166.5, \ 154.2, \ 136.6, \ 136.5, \ 134.4, \ 133.5, \ 131.1, \ 131.0, \ 130.8,$ 130.6, 129.6, 129.0, 117.7 (t, J = 238.9 Hz), 80.5, 72.8 and 72.3, 64.3 and 63.4, 59.1 and 58.9, 52.5, 50.5 (t, J = 21.1Hz) and 49.7 (t, J = 21.7 Hz), 28.8, 27.5, 19.8, rotamers; IR (thin film) 3074, 2933, 1728, 1700, 1603, 1589, 1474, 1395, 1270, 1111 cm⁻¹; MS (ESI) m/z 648.4 (M + K⁺), 632.2 (M + Na⁺), 610.3 (M + H⁺); ESI-HRMS m/z 632.2622 (M + Na⁺, $C_{34}H_{41}F_2NO_5NaSi$ required 632.2614). Compound **20**: $[\alpha]^{20}D$ 14.4 (c 0.74, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 8.06– 8.05 (m, 2H), 7.75-7.44 (m, 13H), 6.50 (td, J = 55.8, 5.4 Hz,1H), 5.82 (br, 1H), 4.36-4.14 (m, 2H), 4.03-3.91 (m, 1H), 3.83-3.69 (m, 2H), 3.58-3.41 (m, 1H), 1.41, 1.32 (2s, 9H), 1.08 (s, 9H), rotamers; ¹⁹F NMR (282 MHz, acetone- d_6) δ -116.47 to -117.75 (ddd, J = 293.1, 10.2, 10.7 Hz, 1F), -123.22 to -124.62 (dddd, J = 291.3, 55.8, 16.4, 16.9 Hz, 1F); ¹³C NMR $(75.5 \text{ MHz}, \text{ acetone-}d_6) \delta 166.1, 154.9 \text{ and } 154.7, 136.3, 135.4,$ 134.4, 134.0, 130.8, 130.7, 130.4, 129.5, 128.8, 120.7, 117.5 (t, J = 240.6 Hz), 80.2 and 80.1, 73.8 and 73.5, 64.8 and 63.9, 58.8 (t, J = 6.9 Hz), 53.9 and 53.3, 48.1 (t, J = 21.4 Hz) and 47.3 (t, *J* = 20.3 Hz), 28.6, 27.2, 19.9, rotamers; IR (thin film) 3073, 2933, 1728, 1700, 1602, 1589, 1473, 1394, 1270, 1113, 709 cm⁻¹; MS (ESI) m/z 648.3 (M + K⁺), 632.2 (M + Na⁺), 610.3 (M + H⁺); ESI-HRMS m/z 632.2628 (M + Na⁺, C₃₄H₄₁F₂NO₅NaSi required 632.2614).

(2S,3S,4R)-N-tert-Butyloxycarbonyl-4-tert-butyldimethylsiloxy-3-difluoromethyl-2-(tert-butyldimethylsiloxymethyl)pyrrolidine (22). To a 0 °C solution of 19 (460 mg, 0.76 mmol) in THF (20 mL) was added TBAF (0.76 mL, 1 M in THF, 0.76 mmol) dropwise. The mixture was warmed to room temperature and stirred until the reaction was shown to be complete by TLC. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 3:1) to afford a clear oil (207 mg), which was solved in CH_2Cl_2 (10 mL) and cooled to 0 °C. To the solution was added DMAP (10 mg, 0.08 mmol) and imidazole (125 mg, 1.84 mmol), followed by a solution of TBDMSCI (138 mg, 0.91 mmol) in CH₂Cl₂ (2 mL). The mixture was warmed to room temperature and stirred for 2 h. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 4:1) to afford a clear oil (258 mg), which was solved in MeOH (3.5 mL) and cooled to 0 °C. Then, to the resulting solution was added a saturated solution of ammonia in methanol (15 mL). The mixture was stirred at room temperature for 28 h. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 4:1) to afford a clear oil (180 mg), which was solved in DMF (3 mL) and cooled to 0 °C. To the resulting solution was added DMAP (40 mg, 0.33 mmol) and imidazole (1.20 g, 17.6 mmol), followed by a solution of TBDMSCl (2.00 g, 13.27 mmol) in DMF (4 mL). The mixture was then stirred for 2.5 h at room temperature. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 50:1) to afford 22 as a clear oil (225 mg, 60%). $[\alpha]^{20}$ _D +6.1 (*c* 0.59, acetone); ¹H NMR (300 MHz, acetone $d_6) \; \delta \; 6.37{-}5.96$ (m, 1H), 4.75 (q, J = 7.5 Hz, 1H), 4.06–3.95 (m, 2H), 3.77-3.64 (m, 2H), 3.13 (dd, J = 6.6, 6.9 Hz, 1H), 2.80-2.65 (m, 1H), 1.45 (s, 9H), 0.94, 0.89 (2s, 18H), 0.08 (s, 12H), rotamers; $^{19}\mathrm{F}$ NMR (282 MHz, acetone- $d_6)$ δ -113.24 to -114.72 (m, 1F), -119.20 to -120.98 (dddd, J = 294.3, 137.5,11.6, 12.5 Hz, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) δ 154.2 and 153.9, 118.4 (t, J = 240.1 Hz) and 118.3 (t, J = 240.0 Hz), 80.0 and 79.9, 71.3 (d, J = 3.5 Hz) and 70.7 (d, J = 3.8 Hz), 62.7 and 61.6, 59.2 (t, J = 9.3 Hz), 55.1, 53.4 (t, J = 20.2 Hz) and 52.7 (t, J = 20.2 Hz), 28.8, 26.4, 26.2, 18.8, 18.6, -4.4, -4.8, -5.2, -5.3, rotamers; IR (thin film) 2957, 2932, 1702, 1393, 1257, 1132, 1116, 838 cm^-1; MS (ESI) $m\!/\!z$ 496.3 (M +H⁺); ESI-HRMS m/z 518.2917 (M + Na⁺, C₂₃H₄₇F₂NO₅NaSi₂) required 518.2904).

(2S,3R,4R)-N-tert-Butyloxycarbonyl-4-benzoyloxy-3difluoromethyl-2-(tert-butyldimethylsiloxymethyl)pyrrolidine (21). To a 0 °C solution of 20 (579 mg, 0.95 mmol) in THF (25 mL) was added TBAF (0.95 mL, 1 M in THF, 0.95 mmol) dropwise. The mixture was warmed to room temperature and stirred for 4.5 h. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 3:1) to afford a clear oil (280 mg), which was solved in CH_2Cl_2 (20 mL) and cooled to 0 °C. To the solution was added DMAP (26 mg, 0.21 mmol) and imidazole (373 mg, 5.48 mmol), followed by a solution of TBDMSCI (382 mg, 2.53 mmol) in CH_2Cl_2 (0.5 mL). The mixture was warmed to room temperature and stirred overnight. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 20:1) to afford 21 as a white solid (344 mg, 75%). Mp 96–97 °C; [α]²⁰_D –27.2 (c 0.66, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 8.05 (d, J = 7.2Hz, 2H), 7.67 (t, J = 7.2 Hz, 1H), 7.52 (t, J = 7.5 Hz, 2H), 6.44 (td, J = 55.7, 5.7 Hz, 1H), 5.73-5.69 (m, 1H), 4.27-4.12 (m, 1H))2H), 3.93-3.55 (m, 3H), 3.32-3.16 (m, 1H), 1.47, 1.38 (2s, 9H), 0.94 (s, 9H), 0.12–0.09 (m, 6H), rotamers; ¹⁹F NMR (282 MHz, acetone- d_6) δ -116.85 to -118.10 (dd, J = 56.4, 54.1 Hz, 1F), -123.44 to -124.68 (m, 1F); ¹³C NMR (75.5 MHz, acetone-d₆) δ 166.1, 154.7, 134.4, 130.5, 129.5, 117.5 (t, J = 239.4 Hz) and 117.4 (t, J = 239.6 Hz), 80.2 and 80.0, 73.7 and 73.4, 64.1 and 63.0, 58.9 and 58.7, 53.7 and 53.3, 48.1 (t, J = 21.3 Hz) and 47.1 (t, J = 21.4 Hz), 28.6 and 28.5, 26.3, 18.9, -5.2, -5.3, rotamers; IR (thin film) 2956, 1718, 1695, 1602, 1584, 1474, 1403, 1280, 1122, 1086, 775 cm⁻¹; MS (ESI) *m/z* 508.1 (M + Na⁺), 486.2 (M + H⁺). Anal. Calcd for C₂₄H₃₇ F₂NO₅Si: C, 59.38; H, 7.63; N, 2.89. Found: C, 59.51; H, 7.85; N, 2.86.

(2S,3R,4R)-N-tert-Butyloxycarbonyl-4-tert-butyldimethylsiloxy-3-difluoromethyl-2-(tert-butyldimethylsiloxymethyl)pyrrolidine (23). To a solution of 21 (344 mg, 0.71 mmol) in MeOH (5 mL) at 0 °C was added a saturated solution of ammonia in methanol (10 mL). The mixture was stirred at room temperature for 6 h. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 3:1) to afford a clear oil (250 mg), which was solved in DMF (7 mL) and cooled to 0 °C. To the resulting solution was added DMAP (38 mg, 0.31 mmol) and imidazole (600 mg, 8.82 mmol), followed by a solution of TBDMSCl (1.04 g, 6.89 mmol) in DMF (1 mL). The mixture was then stirred overnight at room temperature. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 40:1) to afford $\mathbf{23}$ as a clear oil (302 mg, 86%). [α]²⁰_D -20.4 (*c* 0.47, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 6.11 (td, J = 56.7, 6.7 Hz, 1H), 4.57 (br, 1H), 4.13 (dd, J = 9.9, 10.5 Hz, 1H), 3.98 (d, J = 7.8 Hz, 1H), 3.72-3.53 (m, 2H), 3.27 (ddd, J = 17.1, 3.6, 3.6 Hz, 1H), 2.92-2.85 (m, 1H), 1.46, 1.45 (2s, 9H), 0.90 (s, 18H), 0.14-0.04 (m, 12H), rotamers; $^{19}\mathrm{F}$ NMR (282 MHz, acetone- $d_6)$ δ -115.75 to -117.20 (m, 1F), -125.4 to -126.9 (m, 1F); ^{13}C NMR (75.5 MHz, acetone- d_6) δ 155.0, 118.9 (t, J = 238.1 Hz) and 118.8 (t, J = 238.3 Hz), 79.8 and 79.6, 72.0 (d, J = 6.5Hz) and 71.6 (d, J = 5.4 Hz), 63.8 and 62.7, 58.8 (t, J = 8.6Hz), 56.4 and 55.8, 49.7 (t, J = 21.1 Hz) and 48.7 (t, J = 20.7Hz), 28.8, 26.4, 26.2, 18.9, 18.7, -4.5, -5.0, -5.1, -5.2, rotamers; IR (thin film) 2957, 1702, 1473, 1398, 1257, 1151, 1118, 837, 778 cm $^{-1}$; MS (ESI) $m\!/z$ 496.3 (M + H^+); ESI-HRMS m/z 518.2925 (M + Na⁺, C₂₃H₄₇F₂NO₅NaSi₂ required 518.2904).

(5S,4S,3R)-N-tert-Butyloxycarbonyl-5-tert-butyldimethylsilyloxymethyl-4-difluoromethyl-3-(tert-butyldimethylsilyloxy)pyrolidin-2-one (24) and (2R,3R,4R)-Ntert-Butyloxycarbonyl-4-tert-butyldimethylsiloxy-3-difluoromethyl-2-(tert-butyldimethylsiloxymethyl)-2-hydroxypyrrolidine (26). To a solution of NaIO₄ (330 mg, 1.54 mmol) in H₂O (6 mL) was added RuO₂·xH₂O (15 mg). The mixture was stirred at room temperature for 5 min and a solution of 22 (225 mg, 0.45 mmol) in EtOAc (6 mL) was added dropwise. Then, the mixture was stirred at room temperature for 16 h. H₂O (20 mL) and EtOAc (20 mL) were added and the aqueous layer was extracted with EtOAc (2 \times 15 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 60:1, then 10:1) to afford 24 as a clear oil (92 mg, less polar, 40%) and 26 as a clear oil (76 mg, more polar, 33%). Compound 24: $[\alpha]^{20}_{D}$ +18.7 (c 0.57, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 6.28 (td, J = 55.6, 7.2 Hz, 1H), 4.72 (d, J = 10.2 Hz, 1H), 4.32 (d, J = 8.7 Hz, 1H), 4.10 (d, J = 11.1 Hz, 1H), 3.86 (d, J = 12.3 Hz, 1H), 2.95-2.84 (m, 1H), 1.52 (s, 9H), 0.91, 0.90 (2s, 18H), 0.19-0.06 (m, 12H), rotamers; $^{19}\mathrm{F}$ NMR (282 MHz, acetone- $d_6)$ δ -115.06 to -116.39 (dd, J = 54.1, 54.4 Hz, 1F), -119.00 to -120.31 (m,1F); $^{13}\mathrm{C}$ NMR (75.5 MHz, acetone- $d_6)$ δ 171.8 and 171.7, 150.6, 118.1 (t, J = 239.0 Hz), 83.8, 72.5 and 72.4, 61.5, 56.6 and 56.5, 49.0 (t, J = 22.1 Hz), 28.5, 26.5, 26.3, 19.0, 18.9, 1.6, -3.5, -4.8, -5.3, rotamers; IR (thin film) 2955, 1789, 1771, 1714, 1473, 1165, 1019, 841 cm⁻¹; MS (ESI) m/z 532.3 (M + Na⁺); ESI-HRMS m/z 532.2702 (M + Na⁺, $\mathrm{C}_{23}\mathrm{H}_{45}\mathrm{F}_{2}\mathrm{NO}_{5}\mathrm{NaSi}_{2}$ reauired 532.2697). Compound **26**: $[α]^{20}_D$ –3.9 (*c* 1.78, CHCl₃); ¹H NMR (300 MHz, acetone- d_6) δ 6.43–6.01 (m, 1H), 5.25– 5.18 (m, 1H), 4.61 (dd, J = 4.8, 5.1 Hz, 1H), 4.40 (d, J = 5.1Hz, 0.34H) and 4.44 (d, J = 5.4 Hz, 0.66H), 4.16 (d, J = 11.4Hz, 0.66H) and 4.05 (d, J = 11.1 Hz, 0.34H), 3.92 (d, J = 8.7

Hz, 1H), 3.72–3.62 (m, 1H), 2.98–2.81 (m, 1H), 1.48 (s, 9H), 0.93, 0.92 (2s, 18H), 0.13–0.07 (m, 12H), rotamers; ¹⁹F NMR (282 MHz, acetone- d_6) δ –112.39 to –114.31 (dddd, J = 298.36, 174.00, 14.66, 12.69 Hz, 1F), –117.63 to –119.52 (dddd, J = 297.37, 168.14, 11.21, 13.32 Hz, 1F); ¹³C NMR (75.5 MHz, benzene- d_6) δ 154.0 and 153.8, 117.5 (t, J = 240.1 Hz), 80.5, 80.2, 71.6 (d, J = 9.2 Hz) and 70.9 (d, J = 5.8 Hz), 61.2 and 60.2, 57.1 (d, J = 9.1 Hz), 49.2 (t, J = 21.5 Hz) and 48.2 (t, J = 20.6 Hz), 28.5, 26.0, 25.7, 18.2, 18.1, –4.8, –5.0, –5.4, –5.6, rotamers; IR (thin film) 3463, 2956, 1704, 1474, 1369, 1257, 1170, 1133, 839, 779 cm⁻¹; MS (ESI) m/z 529.3 (M + NH₄⁺); HRMS-ESI m/z 534.2849 (M + Na⁺, C₂₃H₄₇F₂NO₅NaSi₂ required 534.2853).

(5S,4R,3R)-N-tert-Butyloxycarbonyl-5-tert-butyldimethylsilyloxymethyl-4-difluoromethyl-3-(tert-butyldimethylsilyloxy)pyrolidin-2-one (25) and (2R,3S,4R)-Ntert-Butyloxycarbonyl-4-tert-butyldimethylsiloxy-3-difluoromethyl-2-(tert-butyldimethylsiloxymethyl)-2-hydroxypyrrolidine (27). Compounds 25 (260 mg, less polar, 54%) and 27 (10 mg, more polar, 2%) were prepared as clear oils from compound 23 (465 mg, 0.94 mmol), using the same conditions as described for compounds 24 and 26. Compound 25: [α]²⁰_D -7.8 (c 0.74, acetone); ¹H NMR (300 MHz, acetone d_6) δ 6.24 (td, J = 55.3, 2.1 Hz, 1H), 4.91 (d, J = 9.3 Hz, 1H), 4.33 (br, 1H), 4.10 (dd, J = 2.7, 2.7 Hz, 1H), 3.79 (dd, J = 1.8, 2.1 Hz, 1H), 3.11-2.96 (m, 1H), 1.52 (s, 9H), 0.94, 0.90 (2s, 18H), 0.21-0.07 (m, 12H), rotamers; ¹⁹F NMR (282 MHz, acetone- d_6) δ -126.03 to -127.26 (ddd, J = 284.3, 9.7, 7.8 Hz, 1F), -127.79 to -131.08 (ddd, J = 284.5, 26.6, 26.1 Hz, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) δ 171.6, 150.6, 116.6 (t, J =240.1 Hz), 83.5, 71.4 and 71.3, 64.6, 55.5 (t, J = 4.1 Hz), 44.5 (t, J = 19.3 Hz), 28.3, 26.3, 26.2, 19.0, -4.2, -5.1, -5.3, -5.4,rotamers; IR (thin film) 2957, 2932, 1801, 1772, 1720, 1473, 1370, 1311, 1258, 1158, 839, 781 cm⁻¹; MS (ESI) m/z 548.3 $(M + K^{+})$, 532.3 $(M + Na^{+})$; ESI-HRMS m/z 532.2687 $(M + Na^{+})$ Na⁺, C₂₃H₄₅F₂NO₅NaSi₂ required 532.2697). Compound 27: $[\alpha]^{20}$ _D -25.1 (*c* 0.46, acetone); ¹H NMR (300 MHz, acetone-*d*₆) δ 6.13 (td, J = 56.7, 6.9 Hz, 1H), 5.25–5.19 (m, 1H), 4.23– 3.97 (m, 4H), 3.64 (dd, J = 11.4, 9.9 Hz, 1H), 3.01-2.87 (m, 4H), 3.01H), 1.46 (s, 9H), 0.92, 0.90 (2s, 18H), 0.16–0.10 (m, 12H); $^{19}\mathrm{F}$ NMR (282 MHz, acetone- d_6) δ -114.80 to -116.91 (ddd, J =297.93, 53.30, 56.96 Hz, 1F), -124.67 to -124.06 (ddd, J =437.1, 43.71, 20.59 Hz, 1F); ¹³C NMR (75.5 MHz, acetone-d₆) δ 154.7 and 154.3, 118.9 (t, J = 236.2 Hz) and 118.7 (t, J =238.0 Hz), 87.3, 80.5 and 80.4, 77.0 (d, J = 8.3 Hz) and 76.4 (d, J = 9.3 Hz), 63.3 and 62.0, 59.0 and 58.9, 47.0 (t, J = 23.1)Hz) and 46.0 (t, *J* = 21.5 Hz), 28.6, 26.4, 26.0, 19.0, 18.6, -4.7, -5.1, -5.3, -5.4, rotamers; IR (thin film) 3441, 2958, 1705, 1473, 1392, 1368, 1257, 1105, 1058, 838, 779 cm⁻¹; MS (ESI) *m/z* 550.2 (M + K⁺), 534.3 (M + Na⁺); HRMS-ESI *m/z* 534.2853 $(M + Na^{+}, C_{23}H_{47}F_2NO_5NaSi_2$ required 534.2853).

(2S,3R,4S,5S)-N-tert-Butyloxycarbonyl-2-acetyloxy-3tert-butyldimethylsilyloxyl-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidine (28). To a -78 °C solution of $\mathbf{24} \; (92 \text{ mg}, \, 0.18 \text{ mmol})$ in THF (5 mL) was added LiBEt₃H (0.45 mL, 1 M in THF, 0.45 mmol) dropwise. The mixture was then stirred at -78 °C for 1 h and the reaction was quenched with H_2O (2 mL) at -78 °C. After the mixture was warmed to room temperature, H₂O (10 mL) was added and the mixture was extracted with Et₂O (3 \times 15 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 20:1) to afford a clear oil (92 mg), which was solved in CH₂Cl₂ (9 mL). Then, to this resulting solution was added DMAP (17 mg, 0.14 mmol) and Et₃N (0.97 mL, 6.9 mmol), followed by Ac_2O (0.35 mL, 3.70 mmol) dropwise. The mixture was stirred at room temperature for 2 h and the reaction was quenched with H_2O (2 mL). The aqueous layer was extracted with CH_2Cl_2 (3 × 15 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After filtration and removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 25:1) to afford 28 as a clear oil (95 mg, 95%). [α]²⁰_D -23.5 (*c* 1.5, acetone); ¹H NMR (300 MHz, MeOH- d_4) δ 6.27 (d, J = 2.7 Hz, 1H), 6.20 (td, J = 56.4, 7.4 Hz, 1H), 4.57–4.54 (m, 1H), 4.12–4.00 (m, 2H), 3.78–3.73 (m, 1H), 2.78-2.65 (m, 1H), 2.04 (s, 3H), 1.43 (s, 9H), 0.95, $0.87~(2s,\,18\mathrm{H}),\,0.11,\,0.10,\,0.07,\,0.05~(4s,\,12\mathrm{H});\,^{19}\mathrm{F}~\mathrm{NMR}~(282$ MHz, MeOH- d_4) δ -114.00 to -115.28 (ddd, J = 293.99, 11.28, 11.14 Hz, 1F), -117.32 to -118.55 (dd, J = 60.07, 57.25 Hz, 1F); $^{13}{\rm C}$ NMR (75.5 MHz, MeOH- $d_4)$ δ 171.0, 154.9, 117.4 (t, J= 239.3 Hz), 88.9 and 88.8, 82.6, 77.4, 61.6, 60.5 and 60.4, 54.4, 28.7, 26.5, 26.1, 21.5, 19.2, 18.7, -4.4, -4.9, -5.2, -5.5, rotamers; IR (thin film) 2957, 1759, 1710, 1473, 1369, 1257, 1116, 1019, 840 cm⁻¹; MS (ESI) m/z 576.3 (M + Na⁺); ESI-HRMS m/z 576.2969 (M + Na⁺, C₂₅H₄₉F₂NO₆NaSi₂ required 576.2959).

(2S, 3R, 4R, 5S) - N-tert- Butyloxy carbonyl-2-acetyloxy-3-acetyloxtert-butyldimethylsilyloxyl-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidine (29a) and (2R,3R,-4R,5S)-N-tert-Butyloxycarbonyl-2-acetyloxy-3-tertbutyldimethylsilyloxyl-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidine (29b). Compounds 29a (151 mg, 55%) and **29b** (29 mg, 11%) were prepared as clear oils from compound 25 (253 mg, 0.50 mmol), using the same conditions as described for compound 28. Compound 29a: $[\alpha]^{20}_{D}$ –16.1 (c 0.78, MeOH); ¹H NMR (300 MHz, MeOH- d_4) δ 6.39 (d, J = 4.2 Hz, 1H), 6.17 (td, J = 56.4, 6.1 Hz, 1H), 4.77-4.72 (m, 1H), 4.11-4.00 (m, 2H), 3.62-3.53 (m, 1H), 2.70-2.56 (m, 1H), 2.04 (s, 3H), 1.47, 1.42 (2s, 9H), 0.92, 0.88 (2s, 18H), 0.11–0.061 (m, 12H); $^{19}\mathrm{F}$ NMR (282 MHz, MeOH- $d_4)$ δ -114.15 to -115.41 (m, 1F), -120.62 to -121.88 (m, 1F); ^{13}C NMR (75.5 MHz, MeOH- d_4) δ 171.1, 154.5, 117.1 (t, J = 240.2Hz), 82.6, 71.5, 65.2, 64.4, 59.1 (t, J = 5.1 Hz), 49.9 (t, J =19.9 Hz), 28.6, 26.4, 26.2, 21.1, 19.2, 18.8, -5.0, -5.2; IR (thin film) 2958, 2932, 1753, 1716, 1473, 1392, 1369, 1259, 1149, 1113, 839 cm⁻¹; MS (ESI) m/z 592.3 (M + K⁺), 576.3 (M + Na⁺); ESI-HRMS m/z 576.2960 (M + Na⁺, C₂₅H₄₉F₂NO₆NaSi₂ required 576.2959). Compound **29b**: $[\alpha]^{24}{}_{\rm D}$ -42.5 (c 0.97, MeOH); ¹H NMR (300 MHz, MeOH- d_4) δ 6.34 (dt, J = 57.2, 8.1 Hz, 1H), 5.53-5.52 (br, 1H), 5.22 (t, J = 5.4 Hz, 1H), 4.24-3.85 (m, 2H), 3.66-3.55 (m, 1H), 2.98-2.85 (m, 1H), 2.05 (s, 3H), 1.49 (s, 9H), 1.0 (s, 18H), 0.18, 0.16, 0.09, 0.07 (4s, 12H); ¹⁹F NMR (282 MHz, MeOH- d_4) δ -117.56 to -115.87 (m, 2F); ¹³C NMR (75.5 MHz, MeOH- d_4) δ 171.6, 154.6, 117.8 (t, J = 239.4 Hz), 82.2, 72.4, 64.9, 63.5, 58.8 (t, J = 5.8 Hz), 48.0 (t, J = 21.2 Hz), 28.8, 26.4, 26.4, 20.9, 19.2, 19.1, -4.4, -4.6, -4.8, -5.2; IR (thin film) 2958, 1755, 1713, 1473, 1397, 838 cm⁻¹ MS (ESI) m/z 554.2 (M + H⁺); ESI-HRMS m/z 576.2963 (M + Na^{+} , $C_{25}H_{49}F_2NO_6NaSi_2$ required 576.2959).

1-[(2R,3R,4S,5S)-N-tert-Butyloxycarbonyl-3-tert-butyldimethylsilyloxy-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-2-yl]uracil (30a) and 1-[(2S,3R,4S,5S)-N-tert-Butyloxycarbonyl-3-tert-butyldimethylsilyloxy-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-2-yl]uracil (30b). To a stirred solution of 28 (95 mg, 0.17 mmol) and uracil (60 mg, 0.54 mmol) in anhydrous acetonitrile (8 mL) was added N,O-bis-(trimethylsilyl)acetamide (0.30 mL, 0.91 mmol). The reaction mixture was stirred under reflux for 30 min. After the mixture was cooled to 0 °C, TMSOTf (0.08 mL, 0.38 mmol) was added dropwise and the solution was stirred at room temperature for a further 30 min. The reaction was quenched with cold saturated aqueous NaHCO₃ (2 mL) and the resulting mixture was extracted with CH_2Cl_2 (3 \times 15 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 7:1) to give two compounds, the less polar compound 30a (7 mg, 7%, white foam) and the more polar compound **30b** (70 mg, 67%, white foam). Compound **30a**: $[\alpha]^{25}_{D}$ -60.2 (*c* 0.30, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 10.09 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 6.24 (td, J = 55.4, 6.5 Hz, 1H), 5.99 (d, J

= 6.9 Hz, 1H), 5.71 (d, J = 7.5 Hz, 1H), 4.65 (dd, J = 6.6, 6.9Hz, 1H), 4.19 (t, J = 10.8 Hz, 2H), 3.87 (d, J = 10.8 Hz, 1H), 3.16-2.98 (m, 1H), 1.36 (s, 9H), 1.00 (s, 9H), 0.86 (s, 9H), 0.21, 0.05, -0.07 (3s, 12H); ¹⁹F NMR (282 MHz, acetone- d_6) δ -114.75 to -116.14 (m, 1F), -117.48 to -118.79 (m, 1F); ¹³C NMR (100.0 MHz, acetone- d_6) δ 163.2, 154.3, 151.8, 140.6, 117.1 (t, J = 239.68 Hz), 103.1, 81.6, 75.1, 73.6, 63.3, 58.7, 49.0 (t, J = 20.5 Hz), 28.3, 26.5, 25.9, 19.0, 18.2, -4.5, -4.9, -5.1, -5.7; IR (thin film) 3202, 3071, 2958, 1699, 1635, 1463, 1370, 1259, 1164, 839 cm⁻¹; MS (ESI) m/z 628.3 (M + Na⁺), 606.3 (M + H⁺); ESI-HRMS m/z 606.3199 (M + H⁺, $C_{27}H_{50}F_2N_3O_6Si_2$ required 606.3201). Compound **30b**: $[\alpha]^{20}D$ $+7.2 (c \ 0.65, acetone); {}^{1}H \ NMR (300 \ MHz, acetone-d_6) \delta \ 10.12$ (s, 1H), 7.61 (d, J = 8.1 Hz, 1H), 6.40 (d, J = 6.6 Hz, 1H), 6.21 (td, J = 55.5, 6.6 Hz, 1H), 5.60 (d, J = 7.8 Hz, 1H), 4.95 (t, J)= 8.6 Hz, 1H), 4.30 (d, J = 5.7 Hz, 1H), 4.20 (d, J = 11.4 Hz, 1H), 3.68 (d, J = 11.4 Hz, 1H), 3.11–2.95 (m, 1H), 1.37 (s, 9H), 0.97, 0.81 (2s, 18H), 0.13, 0.12, 0.10, 0.06 (4s, 12H); $^{19}\mathrm{F}$ NMR (282 MHz, acetone- d_6) δ -113.70 to -115.00 (ddd, J = 298.2, 12.1, 11.7 Hz, 1F), -117.73 to -119.03 (ddd, J = 297.9, 13.0, 11.7 Hz, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) δ 163.2, 153.0, 151.9, 142.4, 118.0 (t, J = 240.2 Hz), 102.1, 81.7, 71.6 and 71.5, 68.4, 60.3, 58.0 and 57.9, 50.5 (t, J = 20.3 Hz), 28.4, 26.3, 25.9, 18.7, 18.2, -4.5, -5.0, -5.3, -5.5, rotamers; IR (thin film) 3190, 2958, 1701, 1629, 1368, 1259, 1137, 838, 780 cm⁻¹; MS (ESI) m/z 628.3 (M + Na⁺), 606.3 (M + H⁺); ESI-HRMS m/z 628.3025 (M + Na⁺, C₂₇H₄₉F₂N₃O₆NaSi₂ required 628.3020).

1-[(2R,3R,4R,5S)-N-tert-Butyloxycarbonyl-3-tert-butyldimethylsilyloxy-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-2-yl]uracil (31a) and 1-[(2S,3R,4R,5S)-N-tert-Butyloxycarbonyl-3-tert-butyldimethylsilyloxy-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-2-yl]uracil (31b). Compounds **31a** (49 mg, less polar, 77%) and **31b** (8 mg, more polar, 13%) were prepared as white foams from compound 29a (58 mg, 0.10 mmol) and uracil (37 mg, 0.33 mmol), using the same conditions as described for compounds 30a and 30b. Compound **31a**: [α]²⁰_D –43.0 (*c* 0.83, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 10.15 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 6.14 (td, J = 55.8, 5.1 Hz, 1H), 5.87 (br, 1H), 5.56 (d, J = 7.2 Hz, 1H), 4.63-4.60 (m, 1H), 4.52 (d, J = 10.8 Hz, 1H), 4.23 (d, J = 7.5 Hz, 1H)Hz, 1H), 3.82 (d, J = 11.1 Hz, 1H), 2.95-2.82 (m, 1H), 1.42 (s, J)9H), 0.97, 0.91 (2s, 18H), 0.22-0.15 (m, 12H); ¹⁹F NMR (282 MHz, acetone- d_6) δ -117.05 to -120.02 (m, 1F), -124.25 to -126.31 (m, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) δ 163.7, 155.0, 151.9, 140.9, 117.9 (t, J = 239.3 Hz), 102.1, 82.1, 76.9, 75.7, 63.1, 60.0, 46.0 (t, J = 20.5 Hz), 28.4, 26.5, 26.2, 19.3, 18.7, -4.4, -5.0, -5.1, -5.3; IR (thin film) 2933, 1712, 1676, 1373, 1334, 1257, 1148, 1111, 836 cm⁻¹; MS (ESI) m/z 628.3 $(M + Na^{+})$, 606.2 $(M + H^{+})$; ESI-MALDI m/z 628.3033 $(M + H^{+})$ Na⁺, C₂₇H₄₉F₂N₃O₆NaSi₂ required 628.3020). Compound **31b**: $[\alpha]^{20}$ _D -48.7 (*c* 0.35, acetone); ¹H NMR (300 MHz, acetone-*d*₆) δ 10.03 (s, 1H), 7.42 (d, J = 5.7 Hz, 1H), 6.31–6.29 (br, 1H), 6.20 (t, J = 55.2 Hz, 1 H), 5.64 (d, J = 6.9 Hz, 1 H), 4.96 (t, J = 6.9 Hz, 1 H)= 8.1 Hz, 1H), 4.35 (br, 2H), 3.58-3.52 (m, 1H), 3.06-2.88(m, 1H), 1.36 (s, 9H), 0.93, 0.86 (2s, 18H), 0.16, 0.12, 0.11, 0.06 (4s, 12H); ¹⁹F NMR (282 MHz, acetone- d_6) δ -116.88 to -118.10 (m, 1F), -122.99 to -124.31 (ddd, J = 290.9, 18.9, 17.8 Hz, 1F); ¹³C NMR (75.5 MHz, acetone-d₆) δ 163.4, 153.1, 151.8, 142.1, 116.7 (t, J = 238.6 Hz), 101.4, 81.6, 71.5, 70.5, 63.3, 58.6, 48.2, 28.3, 26.2, 26.0, 18.6, 18.4, -5.0, -5.4; IR (thin film) 3200, 3065, 2956, 2931, 2860, 1699, 1630, 1471, 1464, 1368, 1259, 1147, 839, 780 cm⁻¹; MS (ESI) m/z 628.3 (M + Na⁺), 606.3 (M + H⁺); ESI-HRMS m/z 606.3209 (M + H⁺, $C_{27}H_{50}F_2N_3O_6Si_2$ required 606.3201).

1-[(2R,3R,4R,5S)-N-tert-Butyloxycarbonyl-3-tert-butyldimethylsilyloxy-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-2-yl]thymine (32a) and 1-[(2S,3R,4R,5S)-N-tert-Butyloxycarbonyl-3-tert-butyldimethylsilyloxy-4-difluoromethyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-2-yl]thymine (32b). Compounds 32a (30 mg, less polar, 49%) and 32b (19 mg, more polar, 31%) were prepared as white foams from compound 29a (54 mg, 0.098 mmol) and thymine (38 mg, 0.30 mmol), using the same conditions as described for compounds 30a and 30b. Compound **32a**: [α]²⁰_D -56.1 (*c* 0.49, acetone); ¹H NMR (300 MHz, acetone- d_6) δ 10.06 (s, 1H), 7.64 (s, 1H), 6.27 (td, J = 56.0, 3.6Hz, 1H), 5.85 (br, 1H), 4.73 (t, J = 5.4 Hz, 1H), 4.33 (d, J =10.8 Hz, 1H), 4.25-4.22 (m, 1H), 3.83 (dd, J = 2.1, 2.4 Hz, 1H), 2.84-2.81 (m, 1H), 1.88 (s, 3H), 1.39 (s, 9H), 0.98, 0.90 (2s, 18H), 0.19, 0.13 (2s, 12H); ¹⁹F NMR (282 MHz, acetone d_6) δ -121.91 to -123.08 (dd, J = 33.0, 54.71 Hz, 1F), -126.64 to -127.89 (m, 1F); ¹³C NMR (75.5 MHz, acetone- d_6) δ 164.2, 155.0, 151.7, 136.2, 117.4 (t, J = 239.8 Hz), 110.4, 81.8, 76.2, 75.2, 64.2, 59.0, 46.0 (t, J = 20.6 Hz), 28.2, 26.5, 26.0, 19.2, 18.5, 12.9, -4.6, -4.8, -5.1, -5.2; IR (thin film) 3192, 3060, 2957, 2933, 1694, 1472, 1370, 1258, 1147, 1107, 838 cm^{-1} ; MS (ESI) m/z 642.3 (M + Na⁺), 620.3 (M + H⁺); ESI-HRMS m/z $620.3363 \hspace{0.1in} (M \hspace{0.1in} + \hspace{0.1in} H^{+} \hspace{0.1in}, \hspace{0.1in} C_{28}H_{52}F_2N_3O_6Si_2 \hspace{0.1in} required \hspace{0.1in} 620.3357).$ Compound **32b**: [α]²⁰_D -42.2 (*c* 0.61, acetone); ¹H NMR (300 MHz, MeOH- d_4) δ 7.25 (s, 1H), 6.26 (d, J = 6.9 Hz, 1H), 6.12 (t, J = 55.8 Hz, 1H), 4.88 (t, J = 8.1 Hz, 1H), 4.56–4.30 (m, 2H), 3.48 (d, J = 9.9 Hz, 1H), 2.96-2.77 (m, 1H), 1.85 $(s, \ 3H), \ 1.33 \ (s, \ 9H), \ 0.94, \ 0.83 \ (2s, \ 18H), \ 0.12, \ 0.10, \ 0.09,$ 0.01 (4s, 12H); ¹⁹F NMR (282 MHz, MeOH- d_4) δ -118.13 to -119.38 (ddd, J = 287.6, 9.3, 9.7 Hz, 1F), -124.4 to -125.7(ddd, J = 287.2, 24.3, 22.0 Hz, 1F); ¹³C NMR (75.5 MHz, MeOH- d_4) δ 116.3, 154.2, 152.8, 139.5, 117.0 (t, J = 239.7Hz), 110.2, 82.8, 71.9, 71.1, 63.7, 59.1, 48.7 (t, J = 21.7 Hz), 28.5, 26.4, 26.1, 19.0, 18.7, 12.5, -5.0, -5.2, -5.3, -5.4; IR (thin film) 3194, 3060, 2957, 2932, 2860, 1693, 1473, 1369, 1259, 1148, 838, 780 cm⁻¹; MS (ESI) m/z 620.0 (M + H⁺); ESI-HRMS m/z 642.3179 (M + Na⁺, $C_{28}H_{51}F_2N_3O_6NaSi_2$ required 642.3177).

1-[(2R,3R,4R,5S)-N-tert-Butyloxycarbonyl-3-hydroxy-4-difluoromethyl-5-(hydroxymethyl)pyrrolidin-2-yl]uracil (33). To a 0 °C solution of 31a (40 mg, 0.066 mmol) in THF (10 mL) was added TBAF (0.16 mL, 1 M in THF, 0.16 mmol) dropwise. The mixture was stirred at room temperature for 1.5 h and the reaction was quenched with H_2O (10 mL). Then, the mixture was extracted with EtOAc (3 \times 20 mL). The combined organic phases were washed with brine and dried over anhydrous Na₂SO₄. After removal of the solvent, the resulting residue was purified by flash chromatography (hexane/ethyl acetate, 1:2.5) to give 33 as a white foam (20 mg, 80%). $[\alpha]^{20}_{D}$ -87.4 (c 0.46, H₂O); ¹H NMR (300 MHz, MeOH- d_4) δ 8.35 (d, J = 8.4 Hz, 1H), 6.21 (td, J = 56.03, 3.3 Hz, 1H), 5.84 (br, 1H), 5.67 (d, J = 5.7 Hz, 1H), 4.50 (br, 1H), 4.21-4.13 (m, 2H), 3.63 (d, J = 11.1 Hz, 1H), 2.87-2.70 (m, 1H), 1.39 (s, 9H); $^{19}{\rm F}$ NMR (282 MHz, MeOH- $d_4)$ δ -119.87 to -123.53 (m, 1F), -126.94 to -129.31 (m, 1F); ¹³C NMR (75.5 MHz, MeOH- d_4) δ 166.3, 155.8, 152.7, 142.7, 117.8 (t, J = 238.4Hz), 102.3, 83.0, 77.2, 74.7, 62.2, 59.8, 46.3 (t, J = 20.8 Hz), 28.5; IR (thin film) 3398, 2925, 2854, 1704, 1472, 1396, 1371, 1085, 808 cm⁻¹; MS (ESI) m/z 777.3 (2M + Na⁺), 755.2 (2M + H⁺), 400.0 (M + Na⁺); ESI-HRMS *m*/*z* 400.1282 (M + Na⁺, $C_{15}H_{21}F_2N_3O_6Na$ required 400.1291).

1-[(2R,3R,4R,5S)-N-tert-butyloxycarbonyl-3-hydroxy-4-difluoromethyl-5-(hydroxymethyl)pyrrolidin-2-yl]thymine (34a). Compound 34a (14 mg, 74%) was prepared as a white foam from compound 32a (30 mg, 0.049 mmol), using the same conditions as described for compound 33. $[\alpha]^{20}{}_D$ -78.5 (c 0.43, MeOH); ¹H NMR (300 MHz, MeOH-d₄) δ 8.26 (s, 1H), 6.20 (td, J = 55.9, 3.6 Hz, 1H), 5.83 (br, 1H), 4.50-4.47 (br, 1H), 4.23 (d, J = 11.7 Hz, 1H), 4.13–4.10 (m, 1H), 3.65 (d, J = 10.8 Hz, 1H), 2.87-2.72 (m, 1H), 1.86 (s, 3H),1.39 (s, 9H); $^{19}\mathrm{F}$ NMR (282 MHz, MeOH- $d_4)$ δ -119.73 to -123.38 (m, 1F), -126.87 to -129.15 (m, 1F); ¹³C NMR (75.5 MHz, MeOH- d_4) δ 166.6, 155.9, 152.8, 138.6, 117.8 (t, J = 239.5Hz), 111.1, 83.1, 77.0, 74.6, 62.2, 59.9, 46.3 (t, J = 20.9 Hz), 28.5, 12.4; IR (thin film) 3459, 3061, 3000, 2940, 1712, 1678, 1660, 1636, 1475, 1385, 1226, 1088, 773 cm⁻¹; MS (ESI) m/z 430.3 (M + K⁺), 414.2 (M + Na⁺); ESI-HRMS m/z 414.1438 $(M + Na^{+}, C_{16}H_{23}F_2N_3O_6Na \text{ required } 414.1447).$

1-[(2S,3R,4R,5S)-N-tert-Butyloxycarbonyl-3-hydroxy-4-difluoromethyl-5-(hydroxymethyl)pyrrolidin-2-yl]thymine (34b). Compound 34b (22 mg, 63%) was prepared as a white foam from compound **32b** (55 mg, 0.089 mmol), using the same conditions as described for compound **33**. $[\alpha]^{20}_{D}$ -28.6 (c 0.79, MeOH); ¹H NMR (300 MHz, MeOH- d_4) δ 7.29 (s, 1H), 6.19-6.15 (br, 1H), 6.18 (td, J = 56.1, 5.4 Hz, 1H), 4.54 (br, 1H), 4.36–4.26 (m, 1H), 4.21 (d, J = 6.0 Hz, 1H), 3.48 (d, J = 11.7 Hz, 1H), 2.95-2.79 (m, 1H), 1.87 (s, 3H), 1.34 (s, 31))9H); ¹⁹F NMR (282 MHz, MeOH- d_4) δ –118.01 to –119.24 (dd, J = 15.3, 15.2 Hz, 1F), -124.54 to -125.84 (ddd, J = 292.22, 15.23, 15.79 Hz, 1F); ¹³C NMR (75.5 MHz, MeOH-d₄) δ 166.5, 154.5, 152.9, 140.1, 118.1 (t, J = 238.4 Hz), 109.6, 82.6, 72.5, 70.0, 60.8, 60.2, 47.0, 28.5, 12.4; IR (thin film) 3396, 2928, 1691, 1477, 1370, 1264, 1145, 776 cm⁻¹; MS (ESI) m/z 430.2 (M + K⁺), 414.3 (M + Na⁺), 392.3 (M + H⁺); ESI-HRMS m/z414.1439 (M + Na⁺, $C_{16}H_{23}F_2N_3O_6Na$ required 414.1447).

1-[(2S,3R,4S,5S)-*N*-tert-Butyloxycarbonyl-3-hydroxy-4difluoromethyl-5-(hydroxymethyl)pyrrolidin-2-yl]uracil (35). Compound 35 (36 mg, 85%) was prepared as a white foam from compound 30b (68 mg, 0.11 mmol), using the same conditions as described for compound 33. [α]²⁵_D +2.8 (c0.97, MeOH); ¹H NMR (300 MHz, MeOH- d_4) δ 7.56 (d, J = 7.5 Hz, 1H), 6.30 (d, J = 6.3 Hz, 1H), 6.19 (td, J = 55.9, 6.6 Hz, 1H), 5.70 (d, J = 8.1 Hz, 1H), 4.88–4.82 (m, 1H), 4.25– 4.22 (m, 1H), 4.10–4.00 (m, 1H), 3.60–3.52 (m, 1H), 2.80–2.68 (m, 1H), 1.46, 1.36 (2s, 9H); $^{19}\mathrm{F}$ NMR (282 MHz, MeOH- d_4) δ –113.74 to –115.36 (m, 1F), –120.49 to –122.04 (m, 1F); $^{13}\mathrm{C}$ NMR (75.5 MHz, MeOH- d_4) δ 166.3, 154.0, 152.9, 143.1, 118.7 (t, J=240.2 Hz), 102.2, 82.7, 70.9 and 70.8, 70.3, 60.3, 59.1, 50.2 (t, J=18.3 Hz), 28.5, rotamers; IR (thin film) 3589, 3523, 3318, 3043, 1702, 1660, 1631, 1481, 1389, 1240 cm^{-1}; MS (ESI) m/z 777.3 (2M + Na⁺), 755.3 (2M + H⁺), 628.3 (M + Na⁺), 400.2 (M + Na⁺); ESI-HRMS m/z 400.1293 (M + Na⁺, C₁₅H₂₁F₂N₃O₆Na required 400.1291).

Acknowledgment. We thank the National Natural Science Foundation of China (Nos. 20325210 and 20472105), Ministry of Education of China, and Shanghai Municipal Scientific Committee for funding this work.

Supporting Information Available: Crystallographic data (CIF) and ORTEP drawing for the compounds **21** and **30a**; copies of ¹H NMR and ¹³C NMR spectra of compounds **4**, **5**, and **8–35**. This material is available free of charge via the Internet at http://pubs.acs.org.

JO050057+